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 Summary	
Osteoarthritis (OA) is the most prevalent musculoskeletal disease in humans, characterized by a 
progressive degeneration of the articulation that causes pain and disability in a large percentage of 
the population. In this pathology, the joint environment becomes predominantly catabolic and 
concentrations of circulating pro-inflammatory factors significantly increase as compared to non-
pathological conditions. Up to date, existing treatments can be effective in reduction of pain and 
improvement of mobility, but none of the available therapies is able to stop the progression of the 
disease.  
Non-degenerative cartilaginous lesions can be currently treated with cell-based approaches, 
consisting of the implantation of autologous chondrocytes into the defect site, those cells being 
isolated from presumable non-affected areas of articular cartilage. Differentially, OA is considered 
a contraindication for such treatments and, in the scarce cases they have been used for patients with 
degenerative traces, failure is reported as the more common long-term outcome. Possible causes of 
these results are the inferior chondrogenic capacity and phenotype stability demonstrated for 
articular chondrocytes (AC) harvested from affected joints, but also, the detrimental conditions of 
the OA environment, potentially compromising the performance of any implanted cell-based 
product.   
Nasal chondrocytes (NC) represent an alternative source for cell and tissue engineering approaches, 
since they can be obtained from a compartment that is not affected (i.e., the nasal septum), and 
show more reproducible capacity to generate functional cartilaginous tissues as well as similar 
responses to mechanical and inflammatory stimuli than AC. In fact, tissue engineered cartilage 
derived from nasal chondrocytes (N-TEC) have been already used in the clinic for the treatment of 
post-traumatic cartilage lesions, but not results are generated regarding their potential to 
additionally treat OA defects. In order to assess such potential, it is necessary to evaluate if N-TEC 
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can survive and maintain their tissue-like properties in the pro-inflammatory and catabolic OA 
environment, to which cells from the different joint tissues (cartilage, synovial membrane and 
subchondral bone) contribute.  
The pillar of this thesis, my PhD dissertation, consists on the exploration of the suitability of N-
TEC for the treatment of OA lesions. Therefore, this manuscript summarizes methods and 
outcomes resulting from investigating the interactions between nasal chondrocytes and cells/tissues 
from OA-joints, as an approach to establish the possible compatibility of N-TEC within an OA 
cartilage defect. Results showed that N-TEC could maintain their cartilaginous properties, when 
exposed in vitro to inflammatory stimuli as those found in OA joints, and positively influence the 
inflammatory profile of cells from OA joints through secreted factors. Moreover, N-TEC were able 
to survive and engraft into OA compartments simulated in vivo, while preserving cartilaginous 
matrix properties and dampening inflammation, as observed in vitro.  
Acknowledging the positive and wide compatibility of N-TEC within OA environments that I 
demonstrated, the clinical application of autologous N-TEC was tested in two patients with 
advanced OA, who would have been otherwise considered for partial knee – prosthetic - 
replacement. After 14 months of implantation, patients have reported reduced pain as well as 
improved joint function and life quality; all findings indicating that N-TEC can be envisioned as a 
therapeutic approach for the repair of osteoarthritic knee cartilage defects. To assess efficacy of 
this procedure, a phase II trial would be required in a larger cohort of patients. 
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 Aims	of	the	thesis	
 
 General	aim	
Investigate the compatibility of tissue engineered cartilage generated with nasal chondrocytes (N-
TEC) with an osteoarthritic (OA) simulated environment. 
 
 
 Specific	aims	
 
I. Determine the capacity of N-TEC to form and maintain cartilaginous properties, when 
exposed in vitro to factors secreted by OA cells/tissues and pro-inflammatory cytokines. 
II. Evaluate the potency of N-TEC released factors to damper the production of inflammatory 
and catabolic molecules in OA cells/tissues in vitro. 
III. Assess the capability of N-TEC to survive, maintain the cartilaginous matrix and integrate 
with surrounding tissues in OA-environments simulated in vivo.   
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 State	of	the	art	
Being the goal of this thesis to assess the potential of a tissue engineering approach for the treatment 
of a specific type of cartilage disease, this state of the art chapter presents the principles of the 
tissue engineering field and how they have been explored for different cartilage repair approaches, 
in which nasal chondrocytes have emerged as a promising cell source. Specific characteristics of 
the disease as well as some suitable models for investigating it, are additionally described in the 
final part of this chapter. 
 Tissue	engineering	(TE)	
Since ancient times manhood have been attracted by the idea of creating living entities, and this 
imaginary has taken us to conceive units with which to replace, repair or regenerate body portions 
of complex whole organisms (1). Popular literary and artistic pieces as the Greek myth of eternally 
devoured – and therefore regenerated - liver of Prometheus (2) or the more modern and well known 
“Lab-created” Frankenstein (3), well document this curiosity.   
For either the achievement of merely structural reposition, a gain in functionality or a combination 
of both, the possibilities to succeed in this intention have evolved along with the scientific and 
technological progresses. While first reports of used substitutes refer to glass eyes as well as 
extremities in wood or metal (4, 5), nowadays prosthesis range between solely material-based 
implants (6) and grafts of biological origin (7).  
Currently, focus is set in the definition of an optimal combination of both materialistic and 
biological approaches that can match the requirements of mechanical stability and biological 
compatibility for different applications (8–10). In this search, the possibility of obtaining better 
biomimetic manners and replacing more specialized structures like tissues and organs - whose 
availability is naturally limited -, came to live with the emergence of the tissue engineering concept 
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(11). The paradigm of this field aims for building up bio-equivalent constructs, by combining cell 
supports (scaffolds) with biological and chemical cues such as cells and 
differentiating/proliferating factors, with the final goal of targeting clinical applications (Fig. 1). 
 
Figure 1. Principles of the tissue engineering (TE) paradigm. Cells isolated from donor biopsies/tissues are cultured 
in vitro and induced to proliferate and/or differentiate in cell supporting materials such as culture vessels or scaffolds. 
Chemical and biological cues (factors) are additionally used to promote the formation of targeted three-dimensional 
biological equivalent. Developed structures are then implanted into the patient in an autologous manner (original image 
from (12)).  
 
3.1.1 Scaffolds	
As one of the primary components of the TE paradigm, the optimal determination of used scaffolds 
is critical. As a pre-requisite, explored scaffolds must be biocompatible (i.e., non-toxic, non-
hazardous, physiologically inert and non-inducers of immunological rejection), besides of 
supporting – or even better promoting- cellular processes of adherence, proliferation and 
differentiation (11). 
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Synthetic materials like metal, ceramics and polymers well fulfill this requirements, and have been 
exploited for applications in hard tissues (13) as the current standard choices in dentistry and 
orthopedic practices. That is the case for example, of the usage of titanium and hydroxyapatite in - 
and as - bone substitutes (14–16). However, such materials are not suitable when biodegradability 
or malleability is desired, as in the case of soft tissues. In those applications, hydrogels and meshes 
are preferred instead, such as in the generation of skin or vascular substitutes (17–19).  
In both cases, development of fabrication technologies has enabled the customization of diverse 
scaffold features like stiffness and porosity in terms of mechanical properties, or adherence and 
degradation kinetics from the biological/chemical perspective (20). Specifications in composition 
for more precise applications are also an alternative, by means of coating (or decoration) with 
molecules of interest as well as the production based on ECM components from the desired 
environment. Of this kind, is the selected scaffolding material for some of the experimental setups 
in this thesis. Those materials could be produced by either de novo formation or de-cellularization 
of a prefabricated matrix (21).  Further possibilities are offered by the developed three dimensional 
printing techniques, allowing not only the functionalization of scaffolds - with the modelling 
composition and structure -, but also the design of anatomically shaped cell supports (22, 23). Fine-
tuning of all mentioned features for specific applications is the focus of current research, and the 
evolution of this field dependent on the biological requirements of employed factors and cells, as 
described below. 
3.1.2 Bioactive	factors	
Aiming for the formation of intended structures with stable and defined biological functions, the 
identification of critical cues triggering different levels of cell/tissue specification has been another 
big focus on the field of tissue engineering.  
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Starting from a basic mix of components supporting the more broad metabolic cellular needs of 
diverse cell types, the formulation of basal media containing salts, buffering solutions and basic 
nutrients like amino acids and glucose, served as preliminary means for maintaining cell viability 
(24). Definition of particular cocktails to sustain more specialized cell types and promote 
proliferation and differentiation, involved the addition of complementary molecules including 
hormones and growth factors. Thus can be linked either with the niche of the cells and expected 
biological function, or generic for diverse phenotypes as is the supplementation with blood serum 
(25).  
Specifically concerning stimulation of cell differentiation, one commonly employed strategy is the 
inclusion of  ECM components in the used scaffolds (21, 26, 27). Regarding soluble factors, the 
elucidation of cell-specific differentiation pathways is fundamental in order to provide appropriate 
stimulation. Among the more commonly used, bone morphogenic proteins (BMP) as wells as the 
transforming, epidermal, fibroblastic, platelet derived and vascular endothelial growth factors 
(TGF-a/b, EGF, FGF-2, PDGF-AA/AB/BB and VEGF), are shown to contribute not only with 
lineage specification, but also with survival and proliferation of an extensive panel of cell 
phenotypes (28), as the ones presented in the following section. A broader description of the 
function of these bioactive factors is presented in the section 3.2.7.2.  
3.1.3 Cells	
Regarding these critical elements of the TE paradigm, the potential of different sources such as 
animal, fetal or patient tissues was initially contemplated for cell procurement (11). Later, the 
discovery and popularity of ‘stem cells’, canonically defined by their abilities of self-renewal and 
differentiation into mature specialized cells, attracted the interest of the scientific community (29, 
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30), guiding tissue engineering efforts towards their exploitation as cell source in view of 
regenerative medicine applications (31).  
These stem cell populations are categorized according to their niche as embryonic (ESC) or adult 
stem/progenitor cells (ASC) if isolated from tissues after birth; but also, in consideration of their 
potency for giving rise to cell phenotypes from all lineages (totipotent), lineages derived from the 
three embryonic layers (pluripotent) or, from one specific lineage (multipotent) (32, 33). The 
diversity of origins and features of these cells conveys a wide range of advantages and limitations. 
ESC for example (34), have an extensive differentiation capacity that implies not only versatility 
on the lineages they could derive, but also a risk of uncontrolled differentiation and  potential tumor 
formation in envisioned clinical applications (35–37). In addition, their procurement from human 
embryos involve relevant ethical concerns that hinder their utilization in regenerative approaches 
(38).  
As an alternative to such ethical issues, the discovery of the possibility to reprogram adult somatic 
cells into induced pluripotent stem cells (iPSC) (39), provided a cell source that was considered 
more viable than ESC. However, several limitations regarding phenotype stability and safety of the 
mechanisms used for inducing its pluripotent status, have restricted their application in clinical 
scenarios (40). 
In contrast, ASC - more commonly acknowledged as mesenchymal stromal cells (MSC) -, do not 
imply major ethical issues and although with a more limited potency than ESC or IPS, represent a 
cell source of easy isolation and with sufficient proliferation and differentiation capacities for being 
used in regenerative medicine applications like bone, cartilage (41), muscle (42) and neural tissues 
(43). Currently, these adult stem cells can be derived from a variety of tissues, as is the case for 
human bone marrow (44, 45), fat (46, 47), umbilical cord blood (48, 49), liver (50), muscle (51), 
pancreas (52), blood (53) and brain (54).  
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These MSC have one essential limitation laying on the heterogeneity of their populations (55). 
Consequently, current efforts are focused on the identification and characterization of specific 
subpopulations that may be more suitable for the different targeted tissues (56–58). Nonetheless, 
despite of continues efforts for consolidating a precise definition of stem cell subtypes by their 
properties and markers (i.e., adherence to plastic, specific surface-antigen expression and 
differentiation potential), this issue remains at the level of a philosophical question (59, 60). 
Instead,  their identity is now considered in the context of the specific microenvironment hosting 
them (i.e., the stem cell niche), categorically associated with the origin of the lineages they are 
capable to differentiate into, as well as their functionality both in vitro and in vivo (61, 62). 
In this framework of disadvantageous heterogeneity in MSC populations, tissue specific 
progenitors stem cells (TSPSC) emerged as a novel cell type of interest for tissue engineering (63). 
The potential of such progenitors, defined by their higher efficacy in lineage-specific 
differentiation, is being explored in the frame of multiple applications such as corneal, intestinal 
and pancreatic repair (64–66).  
Considering all described possibilities and with the perspective of translational applications, the 
primary interest of the TE field is currently focused in standardization of MSC handling, 
optimization of protocols for TSPSC, and identification of cell sources close in lineage to the one 
envisioned; for example, cells isolated from the same targeted tissue  (17). This alternative has the 
advantage of not implying ethical controversies, and the potential of give rise to stable phenotypes 
under appropriate conditions (67, 68).  
Refinement of the combination of scaffolds, cells and factors used for a particular aimed tissue, 
constitute the fundamental principle of current TE investigations, and its evolution is conditioned 
by the progressive understanding of the biology for each cell type or tissue.  
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In this thesis the cartilaginous tissue is the target, therefore, in order to identify the critical elements 
that must be here considered in view of a tissue engineered approach, its main features and 
characteristics are presented in the subsequent sections.    
 Cartilage		
3.2.1 Structure	and	properties	
Cartilage is a form of connective tissue present in different body compartments such as the nose, 
the rib cage and the articulations. It comprises a very specialized extracellular matrix (ECM) along 
with the resident cells, namely the chondrocytes. This tissue is formed during embryonic 
development, upon migration and aggregation of undifferentiated mesenchymal cells from the 
lateral plate that condensate into a cartilaginous anlage. Within this, two distinct populations of 
chondrocytes arise, one that will differentiate towards growth plate chondrocytes (i.e., cells that 
further mature into hypertrophic chondrocytes, ultimately die and are replaced by bone cells); and 
a second that instead, will differentiate into stable chondrocytes (69, 70).    
Cartilage is avascular, one of the reasons why the composition of its ECM is critical for the survival 
and maintenance of the chondrocytes, which in turn, produce and maintain the cartilaginous matrix. 
The whole tissue is solid, firm and enriched in proteoglycans and collagen fibers. This structure 
allows not only the diffusion of substances within the tissue, but also the withstanding of relevant 
mechanical effects according to the different locations where this tissue is present. The diverse 
mechanical properties exposed, consistent with a differential molecular composition of the ECM, 
enables the classification of cartilage into three main types: hyaline (compression resistant), elastic 
(flexible support) or fibrous (deformation resistant) (71, 72). Of particular interest for my 
dissertation is the hyaline cartilage, located in the articular surfaces (i.e., the structures that joints 
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two or more bones), the nasal cavities and the fetal skeletal tissue among other body compartments 
(Fig. 2A). 
In the knee, articular cartilage covers the surfaces of the femur, tibia and patella, conferring stability 
to the whole joint along with muscles, bones, ligaments and synovial tissue (Fig. 2B) (73). Its main 
functional feature is to provide cushioning and frictionless motion to the whole structure.  
 
Figure 2. Cartilage subtypes in the articulations and structure of the knee. (A) Location of cartilage types in the 
human body, discriminating tissues with differential mechanical properties: hyaline (blue), fibrous (red) or elastic 
cartilage (purple) (adapted from (71)). (B) Anatomical configuration of the knee joint showing the articular (hyaline) 
cartilage at the end of the long bones (femur and tibia), surrounded by the joint cavity and covered by the synovial 
membrane. Other joint structures as patella, capsule and fat pad are also indicated (adapted from (71, 74)). 
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3.2.2 ECM	composition	
The hyaline cartilage is characterized for having low cellularity ( chondrocytes are present between 
2 to 5% wet weight), and a highly hydrated ECM (from 60 to 80% of water) enriched in collagens 
and proteoglycans, aside from other non-collagenous proteins (40) (Fig. 3A). The collagen fibers, 
as the main component of the matrix, account for 15% to 22% of its wet weight. The more 
predominant collagen is the type II, but other types comprising I, III, V, VI, XI and XII are also 
present in lower proportions. Fibrils of this extracellular component transition from thin and 
parallel to the surface in the more superficial zone, towards thick and perpendicular at the deeper 
region. This intricate gives the form and tensile strength to the tissue, in combination with other 
elements of the ECM that help stabilizing the network (76) such as the proteoglycans (PG), 
constituting about 10 to 15% of the tissue.  
Those PG are formed by chains of sulfated glycosaminoglycans (GAG) – typically chondroitin 
sulfate - linked to a core protein – typically aggrecan - and agglomerated around a backbone of 
hyaluronic acid (HA), which is a long linear GAG. These arrangements occupy the space in 
between collagen fibrils (Fig. 3B), and allows the dynamic absorption or desorption of water 
molecules, giving the load bearing properties to the joint (77–80).  
Additional ECM components such as non-collagenous proteins, are also relevant for the 
functioning of the joint. Among these,  some of the more relevant are lubricin, that as indicated by 
its name has a lubricating role in the articulation (81, 82); fibromodulin, that interacts with the 
collagen fibers; and different adaptor proteins from the families of matrillins and thrombospondins 
(TSP),  that mediated the interactions between collagen fibrils  and the aggrecan network (83). 
Among this last category, the cartilage oligomeric protein (COMP) (84), member of the TSP 
family, denote a particular interest since it is shown to play a role in skeletal genetic disorders and 
diverse pathological conditions (85).  
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Figure 3. Structure and composition of the extracellular matrix in the hyaline cartilage. (A) Section of hyaline 
cartilage from an articular joint, illustrating the distribution chondrocytes dispersed within the highly hydrated matrix. 
Red color in the matrix indicates high content of glicosaminoglycans (GAG) stained by Safranin-O. (B) Main 
components of the hyaline extracellular matrix showing the arrangement of proteoglycans (PG), formed by changes of 
sulfated glycosaminoglycans (GAG), linked to a core protein and agglomerated around a backbone of hyaluronic acid 
(HA). This intricate interacts with the collagen matrix, mostly composed by fibers of type II collagen. 
3.2.3 ECM	maintenance		
Due to the relevant composition and structure of the cartilaginous ECM, different cell-mediated 
processes are relevant for the preservation of this specialized network, achieved through an 
equilibrated remodeling of the matrix (72). In short, this process involve the synthesis of degrading 
enzymes, as well as the deposition of new ECM molecules by the chondrocytes (86).  
Two main families of proteases are involved in the catabolic process, the matrix metalloproteinases 
(MMPs), and the ‘disintegrins and metalloproteinases with thrombospondin motif’ (ADAMTS). In 
the case of MMPs, 7 types have been shown to be expressed in articular cartilage, from which 
MMP1,-3 and -13 are within the more studied in the context of hyaline cartilage, because of their 
capacity to degrade cartilaginous ECM components including type II collagen, and their 
upregulation in pathological conditions (87). Concerning the ADAMTS family, 19 members are 
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identified in human, categorized according to the substrates they are able to breakdown. In articular 
cartilage, ADAMTS4 and -5 are the more studied, mostly due to their aggrecanase function (88).  
In terms of factors promoting of the anabolic processes, TGF-β is considered the main morphogen  
playing a role in the synthesis of cartilaginous ECM molecules including proteoglycans and 
collagen, through different mediators (86, 89). This factor is also necessary for the proper formation 
of articular cartilage at early stages of development, and its deficiency linked with multiple 
pathological phenotypes of the musculoskeletal system (90, 91). A more comprehensive 
description of factors promoting cartilage formation, as well as their associated roles, is presented 
in the section 3.2.7.2.  
In normal conditions, the homeostasis of the whole structure is maintained because of the balance 
between synthesis of matrix components and degradative enzymes. However, an alterations in any 
of the ECM component or in the phenotype of the joint cells cause a disparity in the metabolism, 
that may evolve into cartilage damage and further development of pathological conditions (71).  
3.2.4 Cartilage	damage	and	therapeutic	options	
As stated before, the tissue homeostasis is disrupted upon events such as trauma, mechanical 
misalignment, genetic factors causing structural and functional damages, or any other potential 
lesion trigger (92). On adults, the intrinsic repairing capacity of cartilage is limited, and existing 
lesions can remain non- or mis-healed if not treated. Clinically, this causes pain and physical 
disability on individuals that might ultimately generate a degenerative joint environment.  
Two main types of lesions can be distinguished in the articular cartilage: Focal and degenerative. 
In focal injuries, the damage is restricted to a well limited area and usually a consequence of trauma 
(93). In degenerative cartilage lesions instead, both the area and the depth of the lesion are 
progressively enlarged with the occurrence of additional damage, triggered by a non-corrected 
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mechanical or metabolic imbalance (92). In both cases, when only the cartilaginous – and no the 
subchondral bone - layer is involved, the capacity of the tissue for spontaneous healing is very 
limited. In cases where the subchondral compartment is affected and stromal cells may reach the 
cartilage, the defect is filled up with fibrous cartilage, lacking the  properties of the hyaline one 
(94). 
For the treatment of symptomatic degenerative defects, a set of strategies is used in order to relief 
pain or resurface the articulation. Among the available, the so-called “conservative” therapies, 
consisting on the administration of analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs) 
(95), are merely palliative. Main limitations of this approaches, reside on the variable responses 
between patients, the limited potency of the effects and the non-indicated long term usage (96).  
Additional pharmacological management of the pain, involves the minimally invasive intra-
articular injections of glucocorticoids to locally maximize the anti-inflammatory effect, or of 
hyaluronic acid, to ameliorate the shock effect and lubricate the joint (97). In the first case, only 
short term benefit of the treatment has been observed, and its usage controversial due to  potential 
risks of adverse events concerning infections and cardiovascular events even at low dosages (98, 
99). Regarding hyaluronic acid injections, they are widely used in the clinics due to its effective 
and temporary pain reducing outcomes. However, lack of evidence about optimal formulation and 
dosage, limits the understanding of its real effects and mechanism of action (100). This lack of 
knowledge, along with the limitations on assessing effects on symptoms other than pain; make 
necessary the discovery, development and optimization of alternative therapeutic agents such as 
potentially able of delaying/stopping (i.e., modifying) the progression of posttraumatic lesions 
towards degenerative ones. Such are commonly referred as disease modifying drugs (DMD), and 
are the current goal of several investigations (101).  
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When structural restoration of the articulation is considered, surgical interventions constitute the 
therapeutic alternative. In the first line of treatments, removal of the excess fluids such as synovial 
effusion and loose bodies by lavage, or extraction of abnormal tissue protuberances by 
debridement, are performed with demonstrated improvement of symptoms (102). For stimulating 
the intrusion of bone marrow into the cartilage, and therefore the formation of fibrotic tissue, 
strategies as bone drilling and microfracture are used (103). When the reconstruction of areas with 
damage in both cartilage and bone, the osteochondral autograft/allograft transplantation 
(OCT/OAT) is the choice (104).  
In order to pursue the possibility of addressing further symptoms beyond structural restoration and 
pain reduction, alternative treatments must be used. Among those, cell-based strategies have been 
used as promising for non-degenerative lesions, and due to its relevance for this dissertation, an 
overview of the available options is presented in the next section.  
3.2.5 Cell-based	therapies	for	cartilage	repair	in	non-degenerative	lesions	
In the case of focal lesions, the autologous chondrocyte implantation (ACI) is a strategy commonly 
used. This technique became popularly used for the treatment of full thickness cartilage defects in 
the 90’s, and consist on the isolation of articular chondrocytes (AC) from an unaffected area, to be 
further expanded and injected into the defect, under a flap of periosteum - layer that covers the 
bony structures - as a physical barrier supporting cell retention (105).  
As starting point, the usage of cultured cells instead of tissue specimens from the same patient, was 
advantageous regarding the procurement of high amount of cells for the interventions, overcoming 
restrictions in source availability (106). However, follow up of treated patients in the following 
years, evidenced some drawbacks of the technique such as detachment of the repair tissue 
(delamination) and periosteal abnormal growth (hypertrophy) (107). In addition, other deficiencies 
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on differentiation instability, poor integration, cell loss and matrix degradation were identified as 
the principal causes for treatment failure. The logic subsequent step was the introduction of a 
scaffolding material instead of the periosteal flap, providing better support and mechanical stability 
to the graft. This strategy, recognized as the “second generation” ACI (108), opened the door 
towards the exploration and assessment of different resources, being the collagen-based matrices 
the more satisfactory in terms of repair capacity and no development of hypertrophy (107).  
Further refining of the technique led to the direct implantation of a scaffold pre-seeded with cells, 
approach known as Matrix-based ACI (MACI) or “third generation” ACI (109). This change of 
strategy offered considerable improvement regarding graft stability and handling, and is now the 
standard cell-based approach used for the treatment of focal lesions of limited size (< 4 mm2) (110). 
The more common matrices used in the diverse ACI approaches are listed in Table 1.  
Table 1. Scaffolds used in cell-based approaches for cartilage repair. Comercially available matrices used for the 
different generations of autologous chondrocyte implantations. (Original table from (107) ) 
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3.2.6 Remaining	challenges	of	the	available	treatments	for	cartilage	repair	
In all mentioned cell-based treatments, the need of causing additional morbidity in a tissue with 
already limited capacity for self-repair was not ideal (111, 112). Moreover, none of the operative 
procedures (merely surgical or cell-based) can reproduce the formation of hyaline cartilage, and 
their outcomes are largely variable according to the severity, etiology and size of the lesion. Other 
patient-related factors such as gender, age and physical activity affects the outcomes too (104). 
Because of these limitations and response-variability, no treatment can faithfully repair the 
structural and biological conditions of the tissue in long-term, thus allowing the progressive 
degeneration of the knee. In those cases - in the stages of worse severity -, the partial of total 
replacement of the joint by a prosthesis is required, as a merely structural solution. This last 
intervention, is only indicated for elder patients due to its associated higher risk for revision (i.e., 
the need of a second surgery) (113, 114).  
With this panorama, existing strategies (both pharmacological and surgical) have limitations in 
fully restoring healthy conditions of the joint, and there is a lack of treatment alternatives for the 
management of large size defects  - since ACI has a size restriction -  as well as for degenerative 
ones in young patients – since prosthesis implantation is only indicated for elder patients - (97, 
114).  
As a conclusive remark, it is imperative to explore alternative therapies capable of filling up the 
gap in between treatments and patient needs. In this thesis, the development of a tissue engineering 
approach for the treatment of degenerative cartilaginous lesion is intended, and therefore, some 
considerations regarding the elucidation of TE strategies for cartilage repair, are presented in the 
following section. 
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3.2.7 Tissue	engineering	approaches	for	cartilage	repair	
Considering the described limitations of available surgical interventions, TE strategies have been 
explored in order to further optimize techniques and outcomes, as well as to develop therapeutic 
alternatives for the treatment of large or degenerative defects, especially in young patients (115). 
In particular, the overcoming of two main drawbacks is perused with the implementation of tissue 
engineering strategies; the need of extracting relative large amounts of tissue from the joint that 
might not be even available in large-size or degenerative defects (112), and the lack of structural 
support in the intervened area, potentially causing delamination and periosteal hypertrophy (107). 
Identifying an optimal combination of scaffolds, bioactive factors and cell sources to address those 
challenges, is critical to achieve such aim (116).  
3.2.7.1 Scaffolds	for	cartilage	tissue	engineering	
The more explored cell supports for cartilage TE are the ones used for autologous chondrocyte 
implantation (ACI), i.e., materials based of collagen, hyaluronic acid and polymers; since they have 
been already tested in clinical applications (107). However, such materials offer a limited capacity 
to allow microstructural organization in terms of ECM arrangement (section 3.2.2), and therefore, 
the finding or development of more biomimetic ones is desired (117). 
Aiming for the replication of the biomechanical properties of the articular cartilage, hydrogels 
represent a suitable biomaterial to recapitulate the liquid/solid composition of the tissue (118), 
allowing further optimization of parameters such as density, degradation and stiffness (119). 
Instead, when properties regarding compartmental organization of the tissue are pursued, the design 
of scaffolds mimicking ECM native structure is the contemplated strategy to favor specific cell 
arrangement (120, 121).  
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None of the approaches above mentioned has been successfully implemented in clinical scenarios, 
and their usage mostly restricted to in vitro investigations (117).  Still, for such in vivo studies, a 
scaffold-free cartilaginous tissues can be alternatively used as a model, by the formation three-
dimensional (3D) cell aggregates under adequate chemical stimulus, involving a defined 
chondrogenic medium (122–124). This cartilaginous micro-masses (also called pellets) can be used 
as individual entities (125) and in combination with other materials to produce larger constructs 
(126). 
3.2.7.2 Bioactive	factors	for	cartilage	tissue	engineering	
Bearing in mind the possibilities regarding cell supports, it is also relevant to establish the important 
factors regulating chondrogenic differentiation.  The current broadly-used chondrogenic medium 
was established in the 1990s for 3D pellet cultures of MSC (124), and its basic composition still 
valid. The most relevant factors involved, as well as their associated functions, are summarized in 
Table 2.  
Apart of the components listed above (TGF-β, ITS, Glucose, Dexamethasone, ascorbic acid and 
Sodium pyruvate), many other cues play a role in chondrogenic differentiation. Regarding the 
physical ones, mechanical stimulation and the material properties of the scaffolds such as stiffness, 
are among the more relevant (127, 128). In the case of additional chemical elements, the 
supplementation with small molecules, additional growth factors or specific inhibitors can be 
introduced, when specific functions or pathways are of interest (129–131). Additional factors 
regulating the chondrogenesis, other than the commonly used in the differentiation media, are 
described in Table 3.    
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Table 2. Typical factors involved in the chondrogenic differentiation. Essential culture media supplements for the 
induction of chondrogenesis in cultured cells (modified from (132)). 
3.2.7.1 Cells	for	cartilage	tissue	engineering	
In line with the general approaches in the whole tissue engineering field, the MSCs constitute the 
more broadly explored cell source for cartilage engineering, due to their ample availability from 
multiple tissues, high proliferation capacity and ability to differentiate into chondrocytes (132). 
Nonetheless, up to date none of the developed protocols or explored sources have been able to 
generate a stable long-term cartilaginous phenotype upon in vivo implantation (133), thus 
hindering the clinical application of stem cell-derived chondrocytes (134). One of the main 
challenges that remains, is the undesirable hypertrophic differentiation (i.e., cell enlargement and 
calcification of the matrix) that this cell type undergoes, unavoidably affecting the quality of the 
tissues in long-term (116, 135). Additionally, the broad heterogeneity in phenotypes that have been 
Transforming growth factor beta 
TGF-β 
• Key cartilage-inducing factor 
• Induce expression of the master regulator of chondrogenesis, SOX9, along with SOX5 
and SOX6; further supporting the expression of ECM components such as aggrecan 
and type II collagen  
Insulin/transferrin/selenium 
(ITS) 
• Serum substitute supporting cell viability, metabolism, proliferation and biosynthesis  
• Mediator of glucose uptake  
• Enhancer of DNA synthesis and proteoglycan production  
• Chondrogenesis stimulating factor  
• Antioxidants (Due to the presence of Transferrin and selenium) 
Glucose 
• Major energy source and precursor of GAG (24). 
• Associated with promotion of chondrogenic differentiation and inhibition of apoptosis  
Dexamethasone 
• Up-regulating effect on cartilage-related gene expression. In combination with TGF-
b, it enhances the expression of COL II-XI, aggrecan, COMP and delays the 
expression of COL X (marker of hypertrophy). 
Ascorbic acid • Plays a role on stabilizing the triple helical structures of collagen  
Sodium Pyruvate 
• Energy source 
• Enhancer of the energy metabolism related to the Krebs cycle  
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described among donors, tissue sources, and event between single cells upon clonal selection, 
represents a drawback for the reproducibility of tissue quality, that ultimately affects clinical 
outcomes (section 3.1.3) (136).   
Table 3. Chondrogenic regulating factors. Additional factors relevant in chondrogenesis. 
 
Because of these barriers on the application of MSC, another explored cell source has been the 
targeted tissue itself, which is the articular tissue. Articular chondrocytes (AC) have a high potential 
for cartilage repair since they expose a mature phenotype and have been already employed in 
approaches such as the previously described ACI/MACI (section 3.2.5). However, AC undergo de-
differentiation during in vitro culture, and can only partially recover the original phenotype in 3D 
(137–139). Moreover, the need of isolating them from a healthier compartment that has already 
limitations in self-repair, constitutes a strong disadvantage since it has been associated with site 
co-morbidity, evidenced with reported cases of  reduced joint functionality (111), increased 
Fibroblastic growth factor 
FGF 
• Increases proliferation and proteoglycan production 
• Induces chondrogenic differentiation 
• The expression of specific members of this family is crucial for the proper cartilage 
patterning during embryonic development 
Insulin growth factor 
IGF 
• Increases proliferation and cartilaginous ECM production 
• Has and additive effect on chondrogenesis in combination with TGF-β and BMP 
Bone Morphogenic proteins 
BMPs 
• Enhance cartilage formation through SOX9, and production of ECM molecules such 
as proteoglycans and type II collagen 
• Some of the members of this family inhibit the development of hypertrophic features 
Wingless/integrated-1 proteins/inhibitors 
Wnt 
• Different members of this family play inhibiting or promoting roles in cartilage 
formation 
• Important for cell migration and condensation (adhesion) 
Vascular endothelial growth factor 
(VEGF) inhibitors 
• Given the avascular nature of cartilaginous tissues, the blockage of VEGF pathway 
(mostly by genetic manipulation of the cells and knockout experiments) have 
demonstrated to be chondroinductive/chondroprotective 
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cartilage injury scores (140) and appearance of degenerative changes (141, 142), long term after 
tissue harvesting. 
This scenario leaves a still unfulfilled need of identifying substitute locations from where to isolate 
cartilage in order to produce implantable tissue. In this attempt, chondrocytes from alternative 
sources have been considered as candidates for tissue engineering, as is the case for nasal septum 
(143), rib cage (144), iliac apophysis (145) and ear (146) cartilage. The chondrogenic capacity of 
this sources has been tested and, in some cases even already implemented in clinical applications, 
such as for auricular reconstruction (147). The nasal cartilage in particular, has been explored by 
our laboratory, and others, as a promising cell source for tissue engineering applications. Due to its 
relevance for this thesis, a more detailed depiction of the nasal chondrocytes is presented in the 
following section. 
 Nasal	Chondrocytes	for	cartilage	repair		
During embryonic development of vertebrates, a high regenerative potential and developmental 
plasticity has been demonstrated for cells with neural crest origin, which can be specifically 
programmed by environmental cues, for giving rise to numerous tissues and organs. Neural crest-
derived cells with progenitor properties have been identified in various craniofacial adult tissues, 
like dental pulp and periosteum. Nasal chondrocytes (NC), represent a particular type of neural 
crest derived cells and several studies have indicated their large potential for tissue engineering 
and/or regenerative medicine purposes (148). 
These cells fulfill the mentioned requirements for cell sources in terms safe procurement with 
minimal donor site morbidity (149), possible in vitro expansion and generation of stable engineered 
cartilage (both in vitro and in vivo) (143, 150) (section 3.2.7.1). When compared with articular 
chondrocytes, their superiority has been proven not only regarding their accessibility (in terms of 
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avoided morbidity and intervention simplicity), but also their higher proliferation rates and their 
reduced age-dependent capacity post-expansion to form cartilaginous tissues (151, 152). 
Envisioning the manufacturing of an articular cartilage substitute, NC display similar responses to 
mechanical (153) and inflammatory stimuli (154) than AC, showing its potential for being 
compatible with the articular environment. Previous studies of our group have also demonstrated 
that nasal chondrocytes lack the expression of specific HOX genes – feature associated with tissue 
regeneration capacities –, and that they are able to activate the expression of specific genes of this 
group, according to the HOX-profile of the site where they are implanted, such as the articular 
cartilage (143). This characteristic could be associated with their neuroectodermal origin, different 
that the one from which the articular cartilage (as implantation site) and articular chondrocytes 
arise.  
Provided these features and considering the need of alternative cell sources for TE or cell-based 
approaches, a subsequent stage in the field was the exploration of their usage on those clinical 
indications, particularly settled for treatment of focal defect (105).  With this goal, different animal 
studies have shown the feasibility of implantation of nasal chondrocytes-based engineered 
cartilage, in ectopic (155) and orthotopic compartments (156). In the last model, their capacity to 
contribute with the formation of repair tissue was demonstrated.  
In terms of in human applications, NC (in the form of tissue engineered constructs, N-TEC), 
succeeded in reconstructing nasal alar lobule after tumor resection (149) and, the feasibility and 
safety of utilizing them for the repair of focal lesions in articular cartilage defects, demonstrated in 
the context of a phase I trial performed by our group (157). The efficacy of this treatment is being 
currently investigated in a phase II study (BIOCHIP, http://biochip-h2020.eu).  
This approach has so far been only assessed in the context of focal (post-traumatic) lesions, but its 
potential extension towards the treatment of degenerative cartilaginous defects is unknown. The 
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feasibility of this extension in the context of a degenerative joint disease, namely osteoarthritis, 
constitute the pillar of this thesis. A comprehensive depiction of this pathology is presented in the 
subsequent segment.  
 Osteoarthritis	(OA)	
3.4.1 Definition	and	Symptoms		
This pathological condition is the cause of about 50% of the worldwide musculoskeletal disease 
burden and affects 30% or the elder population (158). It is triggered by an imbalance of the structure 
and metabolism of the joint as a whole, i.e., concerning not only the cartilage but also the adjacent 
tissues; the synovial membrane and the subchondral bone. The pathology is broadly defined as a 
progressive degeneration of the articulation, that causes pain and stiffness as main symptoms, and 
leads ultimately to disability (159).  
Commonly described morphological changes involve progressive loss of the articular cartilage, 
cartilage calcification, subchondral bone remodeling, and mild to moderate inflammation of the 
synovial membrane (160, 161). The severity of this findings, which is mostly estimated 
radiographically or with magnetic resonance imaging, can be graded by means of different 
established scores considering the presence of osteophytes (bone spurs around the articulation), 
joint space narrowing, sclerosis (bone stiffening) and cartilage deformation (162). Although 
various scores are generally accepted, any is recognized as a standard, and the grading of the 
pathology more frequently performed according to local guides of the different clinics or medical 
societies, hindering the possibility of consolidating a clinical picture for the disease.  
For a more thorough disease diagnosis, contribution of external conditions such as mechanical 
injury, physical activity, aging, obesity, metabolic disorders and gender susceptibility must be 
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considered, as well as the possible existence of symptomatic manifestations of OA, without 
radiographic indications of morphological damage (158).   
Regarding biological events, the precise underlying mechanism for the initiation onset are not yet 
elucidated, but several factors converging on transcriptional regulation of inflammatory and 
catabolic cues, are identified as fundamental for the development and progression of disease. This, 
ultimately triggering cartilaginous ECM breakdown among other morphological joint alterations. 
Of relevance for my thesis are these inflammatory and catabolic components. For this reason, a 
more detailed description of their role in the pathology of OA is presented in the following sections.    
3.4.2 Inflammatory	component		
Inflammation is a major factor associated with the risk of both biological and symptomatic 
manifestations of the disease, such as the cartilage loss as well as the occurrence of pain, swelling, 
and stiffness (106). In the joints, inflammation can be observed at the macroscopic level trough 
evident enlargement of the synovial membrane, due the infiltration of inflammatory cells  (163); 
but also, with the presence of synovial effusions caused by an increased secretory activity of the 
cells in the joint tissues (159). More recently, a chronic ‘low-level’ inflammation, referred as 
micro-inflammation, has been highlighted as relevant for the disruption of the joint homeostasis 
and the triggering of degenerative responses (164).   
Pro-inflammatory cytokines such IL1β, TNFα, IL6 and IL8, have been extensively investigated, 
both for their in vivo role and their potential for inducing OA features on in vitro setups (165). 
These inflammatory factors have been showed to induce an increased expression of matrix 
degrading proteins, including matrix metalloproteinases (MMPs) and various types of a disintegrin 
and metalloproteinase with a thrombospondin type 1 motif (ADAMTS) (166–168), as well as to 
down-regulate the expression of anabolic markers such as type II collagen and aggrecan (106).  
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No defined way of action has been yet depicted for the different factors, and its elucidation is rather 
complex considering that multiple cell types are able to produce them and respond to their signaling 
(169). Nonetheless, abundant evidence about the effects of some of the more studied factors in the 
joint metabolism has been reported. In this regard, relevant facts for this thesis summarized below.   
3.4.2.1 IL1β	
This cytokine is considered one of the key factors involved in the pathogenesis of OA. It induces 
inflammatory reactions and catabolic effects independently, as well as in combination with other 
mediators (165). It is produced by the chondrocytes, but also by osteoblast (OB), synovial cells and 
other cells that infiltrate the synovial membrane during an inflammatory event (170–172). In OA 
patients, IL1β levels are increased in synovial fluid, synovial membrane and cartilage, as compared 
to healthy samples (173, 174). In the case of OB isolated from osteoarthritic subchondral bone, 
IL1β  levels do not differ from those detected in healthy donors (172, 175).   
Different studies have described the effects of IL1β in a reduced synthesis of ECM components by 
the chondrocytes, such as type II collagen and aggrecan (176, 177). In addition, the cytokine also 
enhance the production of ECM degrading enzymes including  MMPs and ADAMTS4 (165, 178–
180). As additional effects, IL1β regulate its own secretion by autocrine signaling, additionally 
stimulating the production of other cytokines such as IL6, IL8, CCL5/RANTES and TNFα (181–
184).   
The role of IL1β is not only associated to the OA onset, but also to other pathological conditions 
like diabetes (185), and relevant cell processes like senescence (186). It also has a synergic effect 
in combination with TNFα (187), cytokine that shares some of the IL1β functions in osteoarthritis, 
as explained in the following section.  
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3.4.2.2 TNFα	
Tumor necrosis factor alpha (TNFα), along with IL1β, is considered a relevant inflammatory 
cytokine involved in the pathological processes in OA. It is secreted by the same cells in the joint 
than IL1β, and similarly to the effects attributed to this last one, its increased concentration is also 
observed in joint tissues and synovial fluid in samples of donors affected by the disease (170–172, 
174). Moreover, higher levels soluble receptors of TNFα (TNFsR1 and TNFsR2) have been 
correlated with increased pain, stiffness and physical disability in patients with knee OA (188).  
The effect of TNFα  coincides, in most cases, with the action of IL1β such as in the impairment of 
the metabolic activity towards a reduced production of  ECM components including proteoglycans 
and type II collagen (189, 190), and an increased secretion of pro-inflammatory (IL6, 
IL8, RANTES - regulated on activation, normal T cell expressed and secreted -) and degrading 
molecules (MMPs and ADAMTS) (139, 191). IL1β and TNFα together, induce the secretion of 
other pro-inflammatory cytokines such as IL17 in the cells that infiltrate the synovial layer, and 
IL18 the cells from the joint tissues (106, 165). 
3.4.2.3 IL6	
This cytokine, usually produced in response to IL1β and TNFα, is secreted by  chondrocytes, 
synovial cells, cell infiltrates from the synovial layer, osteoblast and osteochondral tissues isolated 
from osteoarthritic joints (174, 175, 192, 193). In chondrocytes, osteoblast, synovial fluid and 
synovial tissues from OA donors, IL6 levels are higher, in comparison to healthy samples. In 
addition,  concentrations of IL6 are considerably elevated in the synovial fluid from symptomatic 
cartilage defects, and comparable to levels measured in OA samples (192, 194–196). Moreover, 
detection levels correlate with the severity of the lesion, when assessed radiographically (197). 
The effects of IL6 on the joint converge with those exerted by IL1β and TNFα,  decreasing the 
production of type II collagen and increasing synthesis of degrading enzymes, specifically MMPs 
 
 
34 
in chondrocytes and osteoblast (198–200). Nonetheless, its concentrations are of higher order of 
magnitude than the commonly reported for these other two cytokines, facilitating its detection by 
different analytical setups (171, 174).  
3.4.3 Catabolic	imbalance	
As part of the metabolic activity of the articular cartilage, catabolism of the ECM is performed by 
degrading the enzymes with collagenase and aggrecanase activity, MMP1, -3 and -13 as well as 
ADAMTS4 and -5 (section 3.2.3). In pathological scenarios such as OA, circulating levels of this 
enzymes are increased, turning the environment predominantly catabolic (161).  
The mentioned MMPs are detected in the synovial fluid of patients with OA, along with pro-
inflammatory factors like IL6 (201). Studies have mostly focused on the role that MMP13 have in 
this pathology, demonstrating the correlation of increased levels of the enzyme with the appearance 
of early OA signs (202), as well as the feasibility of partially rescuing the phenotype with its 
depletion (203).   
ADAMTS4 and -5 as the more studied members of their family, have been also associated to the 
onset of OA, for being detected at higher levels in samples from patients with OA signs than in 
healthy controls (204–207). Being less characterized than MMPs, contributions of the individual 
enzymes to the disease progression are not yet understood. However, it is known that deletions of 
this two members - ADAMTS4 and -5 - can prevent ECM degradation and OA progression in a 
mouse models (208, 209). Other members of the family might be also involved in the development 
of the OA phenotype, and their role is currently studied in several investigations (210).  
3.4.4 Alterations	in	cartilage-surrounding	tissues	
Occurrence of OA, in different degrees of severity, implies inflammatory responses and 
morphological changes in all joint tissues; including articular cartilage, synovial membrane and 
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subchondral bone.  Regarding the manifestations of those processes, there is a spectrum of cellular 
and molecular phenotypes that varies both between stages of the disease and affected tissues (211).  
3.4.4.1 Synovial	membrane	
Several studies have reported histological evidence of an inflammatory cell infiltrate on synovial 
tissues isolated from OA patients. This inflammation, called synovitis, refers to the thickening of 
this tissue, mostly due the presence of cells such as macrophages and T cells (160). Reported 
inflammation levels in OA samples - considering histological findings and transcriptomic analysis 
-, are higher than in healthy controls but lower than in other inflammatory cartilage diseases such 
as rheumatoid arthritis. This, emphasizing the more micro-inflammatory conditions in OA (171).  
The presence of inflammatory cells in this tissue, increase its secretory activity and results in 
synovial effusions that may be visualized by magnetic resonance imaging (MRI) or ultrasound, and 
that correlate with the presence of pain and dysfunction in the articulation (106).  Such effusions 
contain several pro-inflammatory, pro-angiogenic and ‘pro-repair’ cytokines that are elevated in 
joints with symptomatic cartilage defects and/or osteoarthritis, in concentrations that vary 
according to the pathological status (174, 212). The circulating molecules then, signal trough the 
cells they reach – chondrocytes, osteoblasts or synovial cells itself – and trigger the catabolic 
cascade described in sections 3.4.3 and 3.4.4. 
3.4.4.2 Subchondral	bone		
Articular cartilage is normally avascular, aneural and separated from the subchondral bone by a 
zone of calcified cartilage. Appearance of fissures in this barrier enable vascular invasion into the 
calcified cartilage, and cross-talk between the two tissues through diffusion of small molecules 
(213). Regions of vascular invasion are associated with localized bone marrow replacement by 
fibrous tissue - which is use as therapeutic approach (103) -, but also with the amplification of the 
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pathological signals, while allowing the infiltration of inflammatory cells into the marrow spaces 
and the cartilage (214). 
Some morphological changes include an increased bone density and protrusions of bone into the 
cartilage layer, leading to cartilage tightening and contributing to the stiffening and biomechanical 
impairment of the articulation (215, 216). As the pathology progresses, the coupling of bony 
outgrowths with cartilaginous damage, allow the secretion of fluid, cells and molecules towards 
the joint cavity and between all joint tissues (217).  The subchondral bone itself contributes to the 
production of inflammatory and catabolic factors  (175, 193), but it  also responds to this 
environment by modulating its genomic and secretory profiles in reaction to the circulating 
molecules (175, 218, 219). 
3.4.5 Therapeutic	options	for	OA	defects	
Considering the variety of etiologies, symptoms and anatomical distributions, no standard medical 
management is stablished and used approaches individualized instead. Nonetheless, up to date there 
is no available treatment capable of stopping the progression of the disease or recovering the 
properties of the lost/damaged hyaline cartage (159), and the existing pharmacological and surgical 
approaches are mainly palliative.   
A general line of intervention levels is defined, according to the severity of the disease. As first 
measure, behavioral interventions such as physical activity or dietary changes are recommended to 
patients in order to strengthen the leg structures and reduce body weight; thus decreasing the 
mechanical load and preventing further damage (158). The following approach, which can be 
combined with the first one, consist on the provision of analgesic and/or anti-inflammatory drugs 
(non-steroidal), to later pass to the intra-articular injections of hyaluronic acid or corticosteroids, 
as the general conservative treatment for all cartilaginous lesions (section 3.2.4). In cases of worse 
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severity, the non-reversible (partial or total) replacement of the knee by a prosthesis is the last 
therapeutic option (113, 114).  
In general, a combination of strategies must be considered in order to  achieve better outcomes, 
such as the tailoring of the approaches in accordance with patient conditions, co-morbidities, risk 
factors or individual perception of health status (159). Additionally, it is important to take into 
account that the scope of the treatments is significantly conditioned by the physical activity as well 
as by the post-intervention rehabilitation plans (220). 
In this pathological condition (OA) the treatment with cell-based approaches, such as the stablished 
for focal lesions, is not an option. First, evidence of degenerative signs of the joint is considered a 
contraindication for such procedures (221). Besides, in the scarce cases they have been applied in 
subjects with indications of osteoarthritis, the long-term outcome for the majority of patients has 
been the treatment failure (223), despite of some short and mid-term observed benefits (222). In 
this context, the therapeutic challenge is to develop a therapy able to address both symptomatic and 
structural changes. Therefore, current efforts are focused in the development of implantable grafts 
capable of stopping or inhibiting the structural deterioration caused for the pathology (159), and in 
the identification of appropriate research models that can be used to assess the clinical relevance 
of the new developments. An overview of the models that could be exploited for this purpose are 
described below.  
 
3.4.6 Models	for	the	study	of	osteoarthritis	
No in vitro or in vivo gold standard model is stablished for the assessment of therapeutic agents in 
OA. Therefore, setting up the pertinent conditions able to recapitulate some features of the disease, 
is one of the current goals from both scientific and clinical perspectives (224). This section provides 
 
 
38 
a depiction of the in vitro and in vivo approaches commonly followed in the field, towards the 
development of representative models.  
3.4.6.1 In	vitro		
Laboratory studies using cell-based assays as well as human OA joint tissues have identified a 
number of molecular pathways that are induced by mechanical, inflammatory, and oxidative 
stresses.  In the cartilage, these stimuli results in phenotypic alterations of the chondrocytes, loss 
of homeostasis, and activation of abnormal cell signaling or transcriptomic profiles (225).  
Different models simulating those independent stresses, contemplate the employment of cell 
monolayers, 3D cultures and tissue explants, as well as their exposure to one or more of the stimuli 
above mentioned.  However, considering that not precise mechanisms controlling the OA 
phenotype have been yet elucidated, no physiologically relevant conditions have been achieved 
either. Being the 3D culture system the in vitro model used in this thesis, is worth mention that 
apart of being capable to resemble the ECM composition of native cartilage (226), it is also capable 
to react different inflammatory and mechanical stimuli in the context of a simulated OA 
environment (125, 227).  
Regarding inflammatory factors, the cytokines IL1β and TNFα are classical choices, knowing their 
widely documented catabolic effects on cartilage, and their multiple associations with OA (section 
3.4.3). As alternative sources of pro-inflammatory molecules, the usage medium conditioned by 
inflammatory cells have been also used for the culture the engineered tissues (228). Responses of 
such approaches are often assessed in regards to the histological quality of the tissues, changes in 
matrix composition, as well as in reduced viability and transcriptomic alterations of the 
chondrocytes (229).  
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Tri-dimensional micro-pellets of primary articular chondrocytes, studied in the context of a more 
acute inflammation ‘high dose, short exposure time’, have responded to IL1β – alone or in 
combination with TNFα - with a reduction of GAG and an up-regulation of inflammatory and 
catabolic factors such as IL8, monocyte chemoattractant protein-1 (MCP1) and MMP1 and -13 
(125, 154, 230). Lower concentrations and prolonged exposure time have been also investigated in 
3D cultures of a chondrocyte cell line, by exposing them to the typically used cytokines (IL1β and 
TNFα) and to macrophage conditioned medium. Such exposure leading to the upregulation of 
catabolic markers and reduced expression of ECM components (228). 
These in vitro models have been useful as a preliminary screening to elucidate the responses of 
chondrocytes to different factors, and are desirable for the intention of reducing animal 
experimentation (231). However, two main limitations need to be surpassed in order to obtain 
clinically relevant results; the oversimplified simulation of the pathological features, and the non-
physiological levels of factors and forces, often use to favor an effect. A more representative model 
would include not only the cross talk of biochemical cues among the different joint tissues, but also 
the mixed effect of the inflammatory and mechanical elements (225). 
3.4.6.2 In	vivo	
Considering the described disadvantages of in vitro models in terms of their limited capacity to 
recreate a physiological scenario for translational approaches, in vivo animal models provide a 
better platform to study OA as a disease of the whole joint, and with the possibility of incorporating 
the biomechanical component (232). Nonetheless, it is important to take into account that no animal 
model is suitable for evaluating the efficacy of a potential human therapeutic approach (224, 233), 
and only specific questions can be reliably solved by choosing the more appropriate one.  
Small animal models such as mice, rats, rabbits and guinea pigs as well as large size including goat, 
sheep and horse, offer several advantage and drawbacks that must be considered in regards to the 
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application or intended outcome. Small species are often cheaper, easier to handle and analyze, and 
can usually give faster results. Large animals instead, lack the practical handling but are 
biomechanically and anatomically more similar to the human joins (234, 235). Because of such 
differences, small animal models are more suitable for the study of pathogenesis or 
pathophysiology of the disease, whereas large models shall be used for pre-clinical evaluations of 
drugs and disease modifying agents (236).  
Another relevant aspect of the in vivo models is the possibility of studying naturally occurring or 
induced OA. In the first case, models (small and large) exposed the phenotype with aging, due to 
genetic pre-disposition (or modification), as well as to intrinsic species-specific properties. Its 
relevance lies on the fact, that it makes possible to study the stages of the disease in a non-artificial 
timing, according to the lifespan of the particular model (237, 238). On induced OA, degenerative 
changes in the articulation are triggered by a direct insult to the joint, which can be surgical or 
chemical. The advantage of this model is that it allows the achievement of a faster OA onset, as 
compared to the naturally occurred ones, and that can be used to simulate a post-traumatic lesion, 
one of the common types of OA (239, 240).  
In this thesis different in vitro and in vivo models have been used, in order to evaluate the 
performance of nasal chondrocytes-based tissues in different OA simulating environments. The 
description of such models as well as the derived findings are presented and discussed in the 
following sections.    
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 Evaluation	 of	 the	 compatibility	 of	 tissue	 engineered	 cartilage	
generated	with	nasal	chondrocytes	 (N-TEC)	with	an	osteoarthritic	
(OA)	simulated	environment.	
 Aim	I:	Responses	of	nasal	chondrocytes-based	engineered	cartilage	to	
OA-simulating	inflammatory	conditions	
4.1.1 Introduction	
Inflammation is considered one of the main triggers for the development and progression of 
osteoarthritis (106) along with the mechanical insult (161). Continuous low-level secretion of the 
inflammatory molecules IL1β, 6, 8 and TNFa, referred as chronic inflammation (164), is co-related 
with the production of matrix-degrading enzymes, such as ADAMTS and MMPs that ultimately 
cause cartilage degradation as the most prominent indicator of OA (241). Those factors may be 
produced by the chondrocytes themselves (6, 7) or by the surrounding tissues such as synovial 
membrane (8, 9) and subchondral bone (10, 11). In an OA joint, the presence of these molecules 
would represent a challenge for any cell-based therapy upon implantation. 
Consequently, being the main aim of this thesis to explore the potential application of nasal 
chondrocyte-based engineered cartilaginous tissues (N-TEC) for the treatment of OA lesions, I first 
investigated whether they can withstand a prolonged exposure to OA-simulating factors in vitro. 
These conditions were reproduced either by a combination of the commonly used pro-
inflammatory cytokines (IL1β, 6, and TNFa), or by the secreted factors from osteoarthritic cells 
and tissues. The effect of such stimuli was evaluated in terms of the maintenance of the 
cartilaginous matrix as well as proteomic or transcriptomic alterations, in order to evaluate the 
performance of N-TEC in an OA-joint environment. 
No cell-based strategy has been recognized as conventional for the treatment of OA-lesions yet, 
therefore, no standard cell type was an evident choice to be use as control and for comparison. 
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Nonetheless, healthy articular chondrocytes (AC) were used throughout the entire experimental 
setup to (i) have a reference of the cartilaginous capacity of cells from the targeted tissue (i.e., 
articular cartilage) and to (ii) assess whether effects were specific to the nasal origin of the cells, 
or a general chondrocyte-related feature.   
Responses of human nasal chondrocytes to inflammation have been previously studied using this 
model, either in the context or an acute-like inflammation, by short exposure (3 days) to the 
inflammatory factor IL1β (154), or in a chronified environment, by prolonged exposure to the 
cocktail here used (IL1β, -6, and TNFa) in combination with nutrient deprivation (242). This 
chapter describes the performance of N-TEC under chemically defined, or physiological 
conditions, simulating the inflammatory component of OA in vitro, when cultured in similar 
settings than the stablished for clinical manufacturing of N-TEC.  
 
4.1.2 Results	
4.1.2.1 N-TEC	respond	to	OA-inflammatory	conditions	with	a	reduction	in	GAG	
deposition	and	upregulated	expression	of	inflammatory/catabolic	
mediators		
In order to evaluate the effect of selected inflammatory conditions on N-TEC, nasal (and articular) 
chondrocytes were isolated and chondrogenically differentiated - in the form of 3D macropellets-. 
Engineered tissues were then exposed for up to 14 days to (i) low and (ii) high concentrations of a 
cocktail of the pro-inflammatory cytokines IL1β, IL6, and TNFa, as well as to media conditioned 
by (iii) osteoarthritic osteochondral tissues (OA-OC_CM) or (iv) osteoarthritic synovial cells (OA-
Syn_CM) (Fig. 4A). TECs cultured without chondrogenic/inflammatory factors (in control 
medium, CTR) were used as control samples, and comparison with A-TEC were performed. 
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After exposure to the different conditions, histological characterization of the treated tissues by 
Safranin-O staining, evidenced a high inter-donor variability in all control (CTR) and OA-
inflammatory conditions, as expected for primary cells (Fig. 4B). Indirect assessment of the 
glycosaminoglycan (GAG) content, performed by quantification of the Safranin-O intensity 
(scoring from 0=no stain to 3=dark and even stain), showed a trend for higher GAG in nasal 
chondrocyte-based tissues, in all conditions and time points and as compared to articular 
chondrocytes-based tissues. This differential quality between N-TEC and A-TEC was significant 
for non-OA treated samples (CTR) at both time points, and after 14 days of exposure to High 
Inflammation or OA-Syn_CM. Only non-inflammation treated A-TECs (CTR) were affected by the 
culture time, with a significantly lower GAG content at day 14, that the one measured after 7 days 
of culture. The more detrimental OA-inflammatory condition was found to be the High 
Inflammation, affecting significantly the quality of A-TEC tissues after the first week of treatment, 
and of N-TEC by the end of the culture, as compared to CTR (Fig. 4C).  
For quantifying the effect of tested inflammatory conditions in the GAG content of N-TEC, the 
amount of sulfated glycosaminoglycans in the extracellular matrix of the treated pellets was 
measured and normalized by the amount of DNA; parameter that remained stable within the 
different experimental conditions (Table 4). Similar to previous findings, GAG content of N-TEC 
showed a trend towards reduction in engineered tissues treated with OA-inflammatory conditions. 
No significant changes were detected between baseline (GAG content prior treatment) and N-TEC, 
at any of the OA-simulating conditions and exposure times. Nonetheless, A-TEC underwent a 
significant reduction in the majority of conditions. Exposure to OA-OC_CM did not cause any 
significant effect on the engineered tissues, both nasal and articular chondrocyte-based. A reduction 
in the CTR condition, that was significant for A-TEC, did not permitted a clean discrimination of 
the net effect for the different inflammatory conditions on this parameter (Fig. 5A). 
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Figure 4. Responses of N-TEC and A-TEC to OA-simulating inflammatory conditions. (A) Schematic 
presentation of N-TEC formation and further exposure to different conditions simulating the inflammatory component 
of OA. (B) Histological quality of engineered tissues with nasal (N-TEC) or articular (A-TEC) chondrocytes assessed 
by safranin-O staining. Best and worst tissues shown for control (CTR) and all OA-inflammatory conditions by the 
end of the culture (d14). Scale bar: 100 µm. (C) Quantification of safranin-O staining for N-TEC and A-TEC after 7 
and 14 of exposure to the different experimental conditions. The score indicates 0= No stain, 1= Weak stain, 2= 
Moderately even stain and 3=Even dark stain, parameters based on the “Bern Score” (243). § Indicates significant 
differences between N-TEC and A-TEC at the same time point and condition, * from control at the same cell type and 
time point, and # between time points for the same cell type and condition. P <0.05 considered significant after 
comparison by Kruskal-Wallis and Mann-Whitney with Bonferroni correction.  
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Table 4. GAG and DNA content of N-TEC and A-TEC exposed to OA-simulating conditions. Quantified levels 
of glycosaminoglicans (GAG), DNA and GAG/DNA in the extracellular matrix of engineered tissues (N-TEC and A-
TEC), after exposure to different OA-inflammatory conditions. Values represented as the mean ±SD of 6 to 20 
experimental replicates per condition. Baseline values correspond to the amounts of the indicated parameter prior 
exposure to any condition. *Indicates significant differences with baseline for the corresponding cell type and §between 
cell types for the corresponding timing and condition (for an n of 6 to 20 experimental replicates per condition). 
Comparisons assessed by Kruskal-Wallis. P <0.05 considered significant. 
   DNA (µg) GAG (µg) GAG/DNA 
    N-TEC A-TEC N-TEC A-TEC N-TEC A-TEC 
d0                                    Baseline                               1.8 ± 0.9 1.2 ± 0.7 11.5 ± 11.6 10.4 ± 11.6 6.6 ± 7.7 7.9 ± 6.4 
d7  
Ctr                                        1.6 ± 1.0 1.0 ± 0.7 7.5 ± 7.8 4.6 ± 6.4 4.7 ± 4.5 3.7 ± 3.0* 
Low Inflammation                                        1.2 ± 0.9 1.0 ± 0.7 5.7 ± 6.4 5.1 ± 6.5 7.3 ± 11.7 3.3 ± 2.9* 
High Inflammation                                        2.0 ± 0.9 1.8 ± 0.3 4.3 ± 2.9 4.9 ± 1.7 2.4 ± 1.2 2.6 ± 0.6* 
OA-OC_CM                                        1.8 ± 0.6 1.8 ± 0.2 10.6 ± 9.2 7.6 ± 1.1 6.0 ± 5.4 4.2 ± 0.7 
OA-Syn_CM                                        1.6 ± 1.0 0.8 ± 0.2 5.1 ± 3.6 2.2 ± 0.4 3.0 ± 1.1 2.8 ± 0.9* 
d14  
Ctr                                        1.4 ± 0.9 0.6 ± 0.5 5.3 ± 4.9 2.1 ± 2.8 3.2 ± 1.7 2.5 ± 1.9* 
Low Inflammation                                        1.8 ± 0.6 1.1 ± 0.4 7.9 ± 5.5 4.5 ± 5.2 4.0 ± 2.6 4.0 ± 4.3 
High Inflammation                                        1.9 ± 0.7 1.0 ± 0.3 4.2 ± 2.1 2.3 ± 0.5 2.1 ± 1.0 2.4 ± 0.8* 
OA-OC_CM                                        1.6 ± 0.8 0.9 ± 0.4 6.7 ± 3.8 2.9 ± 2.6 4.5 ± 3.1 2.8 ± 2.0 
OA-Syn_CM                                        1.5 ± 1.2 0.5 ± 0.2*§ 4.1 ± 3.4 0.9 ± 0.9*§ 3.4 ± 1.7 2.2 ± 2.7* 
 
As a complementary analysis, the responses of the culture system in terms of gene expression 
profile were also evaluated. Levels OA associated factors such as IL6, IL8/CXCL8, MMP3, 
MMP13, ADAMTS5 as well as the ECM-cartilage related COL2, 1 and ACAN (encoding genes for 
type II collagen and aggrecan), were screened by RT-PCR for all conditions and time points, 
including an earlier time point (3d). For the majority of the factors, no major trends were identified 
along the different conditions tested. Nonetheless, obtained data indicated a trend for increased 
expression of these genes in the different inflammatory conditions, as compared to baseline 
(expression prior treatment) or to CTR (at the corresponding exposure time).  
Expressed levels of IL6 and MMP3 however, showed a tendency of higher up-regulation in A-TEC 
for the majority of conditions, as compared to N-TEC, just significantly different for MMP3 in the 
Low Inflammation condition at d7. Particularly, in line with the findings derived from the 
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histological analysis, the condition of High Inflammation was the more detrimental one, triggering 
a significantly higher expression of both genes, as compared to CTR, during the first two exposure 
times (d3 and d7). Exposure to OA-OC_CM did not cause any significant effect on N-TEC or A-
TEC, similarly to the observations obtained from the GAG analysis. No differences between times 
of exposure were detected (Fig. 5B).  
 
Figure 5. Effects of OA-inflammatory conditions in GAG content and transcriptomic profile of N-TEC and A-
TEC. GAG/DNA measurements of treated tissues based on nasal (N-TEC) or articular (A-TEC) chondrocytes, in 
different OA-simulating conditions and exposure times. Dashed line indicates GAG content of the Baseline (prior 
treatment). *Indicates significant differences with Baseline for the corresponding cell type. (B) RNA levels of IL6 and 
MMP3 of treated N-TEC (and A-TEC) in different OA-conditions and exposure times. Significant differences between 
conditions at the corresponding timing are indicated with * for N-TEC and * for A-TEC, # Indicates differences with 
baseline and § between cell types at the corresponding timing and condition. Multiple comparisons assessed by Kruskal-
Wallis, followed by with Mann-Whitney with Bonferroni correction. P <0.05 considered significant. 
The findings here described for the histological quality, GAG composition and gene expression 
profiles of treated specimens, show that N-TEC have a superior quality than A-TEC at CTR 
conditions (i.e., not-inflammatory and not-chondrogenic), and indicates that this quality may be 
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better preserved by nasal chondrocyte-based tissues after exposure to OA-simulating conditions. 
Results also show that despite of the high variability between samples, engineered tissues are 
capable of responding to inflammatory conditions, and that this response can be followed by 
changes in the ECM composition such as a reduction in GAG, and by changes in the cellular 
phenotype such as alterations in the gene expression profile. It was additionally observed that no 
significant changes occurred between time points, with exception of A-TEC in CTR condition; and 
that High Inflammation was the more harmful condition while the exposure to OA-OC_CM did not 
trigger any detectable response on N-TEC (or A-TEC).  
4.1.2.2 N-TEC	better	preserve	the	overall	cartilaginous	quality	in	conditions	
physiologically	simulating	the	OA	onset	
Considering that used concentrations of inflammatory factors for the condition of High 
Inflammation are not representative of a physiological scenario, and additionally, that OA-OC_CM 
did not caused any response in the treated cartilaginous tissues; the conditions Low Inflammation 
and OA-Syn_CM were selected for a broader estimation of the responses of N-TEC to OA-
simulating conditions.  
As a complementary analysis for the quantification of the GAG content in the Safranin-O stained 
tissues (Shown in Fig. 4B), a system considering not only the intensity of the staining, but also 
cellular distribution and morphology, namely the Bern Score (243), was used for a more complete 
evaluation of the engineered-tissue quality. This assessment showed that histological quality of N-
TEC was only affected after 7 days of exposure to the condition of Low Inflammation (*P =0.0171). 
Instead, the quality of A-TEC was significantly affected by the OA-Syn_CM at both exposure 
times (*P = 0.0079 at d7 and *P= 0.010 at d14), and this reduction was even significantly lower 
by the end of the culture time (#P = 0.036 between d7 and d14).  
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Comparison between cell sources, evidenced that the quality of N-TEC was significantly higher 
than A-TEC in the majority of conditions, with exception of the Low Inflammation at d14 (Fig. 
6A). Representative images for the quality of the corresponding tissues, stained with Safranin-O 
are shown in Fig. 6B. This better preservation of the cartilaginous extracellular matrix was 
confirmed by immuno-histological detection of type II collagen, in which this component was 
present in N-TEC tissues (both CTR and N-TEC treated), but absent in the A-TEC exposed to OA-
Syn_CM (Fig. 6C).  
To evaluate more thoroughly possible alterations in the cellular phenotype induced by the OA-
simulating conditions selected, gene expression levels of different inflammatory (IL6, IL8), 
catabolic (MMP3, MMP13 and ADAMTS5) and cartilaginous (COL2, ACAN and COL1) factors 
were quantified at day 7. None of the tested conditions significantly regulated the expression of the 
tested factors in N-TEC tissues, as compared to the CTR and as assessed by qRT-PCR analysis. 
However, the pro-inflammatory IL6 and IL8, as well as the catabolic MMP3 were up-regulated in 
A-TEC upon exposure to Low Inflammation. No changes in the expression of cartilage related 
factors were detected by any condition in both cell sources. For some of the modulated factors, 
expression levels in tissues treated with Low Inflammation were significantly higher than in the 
OA-Syn_CM condition (IL6 and MMP13 in N-TEC, IL8 and MMP3 in A-TEC). This last condition 
(OA-Syn_CM), did not modulate the gene expression profile in any of the cell sources used (Fig. 
7A).  
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Figure 6. Cartilaginous properties of N-TEC and A-TEC exposed to Low Inflammation and conditioned medium 
of osteoarthritic synoviocytes (OA-Syn_CM). (A) Histological quality of N-TEC (left) and A-TEC (right) following 
7 and 14 days of exposure to the selected conditions, assessed by the Bern Score. Scale represents arbitrary units from 
0= lower quality to 9 = higher quality. Dashed lines represent the score of tissues in control condition (CTR). Values 
presented as mean ±SD for an n = 7 donors (per cell type), except for OA_CM (n = 5 donors). * Indicates significant 
differences versus CTR; # between time points and § between N-TEC and A-TEC at same time and condition, as defined 
by unpaired (parametric) students T-test. P <0.05 considered significant. (B) Staining of the extracellular matrix for 
GAG by Safranin O and (C) type II collagen (Col II) by immunofluorescent detection (at d14).  
 
To evaluate the effects of the chosen OA-conditions in the secretory profile of N-TEC, 
inflammatory and metabolic factors were quantified in the culture supernatants of N-TEC and A-
TEC after exposure to Low Inflammation or OA-Syn_CM (Table 5). Factors such as MIP1α/CCL3, 
IL12, IL13, IL17, TNFα and INFγ were not detectable in CTR but their secretion induced after the 
treatments. A second group of factors (i.e., MIP1β/CCL4, MCP1/CCL2, IL4, IL6, IL8/CXCL8, 
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IL1RA and RANTES) was already detectable in CTR, but the secreted amounts increased upon the 
different OA-simulating conditions. Among the evaluated panel, factors such as Eotaxin/CCL11 
and IL1β were not modulated in either NC or AC by the exposure to inflammatory conditions. 
RANTES was the only factor for which significant differences were detected between cell sources, 
being up-regulated by A-TEC (and not by N-TEC) in the condition of Low Inflammation. The 
observed modulatory effects in factors classically studied by their relevance in OA (IL1β, IL6, IL8, 
TNFα, RANTES) are illustrated in Fig. 7B.  
 
Figure 7. Transcriptomic and secretory profile of N-TEC and A-TEC exposed to exposed to Low Inflammation 
and conditioned medium of osteoarthritic synoviocytes (OA-Syn_CM). (A) RNA levels of inflammatory (IL6, 
IL8/CXCL8), catabolic (MMP3,-13, ADAMTS5) and cartilaginous factors (COL2,-1, ACAN) on nasal and articular 
chondrocytes from engineered tissues , after 7days of exposes to selected OA-conditions. Dashed line indicates 
expression of tissues in control condition (CTR). # Indicates significant differences versus CTR and * between 
conditions, for the same cell type and time point. (B) Levels of selected secreted factors by N-TEC and A-TEC at d7 
(n = 4 matched donors). Values < 0.1 pg/ml were considered under the limit of detection (n.d. = not detected). * 
indicates significant changes versus CTR and $ between N-TEC and A-TEC at same time point and condition. 
Differences assessed by Mann-Whitney-U analyses. P <0.05 considered significant. 
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All this data indicates, that despite of the up-regulation of different inflammatory/catabolic factors 
upon the treatment with conditions mimicking more physiologically the inflammatory component 
of OA, N-TEC can better preserve their cartilaginous quality than N-TEC. Results also evidenced 
that the cellular phenotype of NC in terms of their gene expression and secretory profile, can be 
less affected than the phenotype of AC when stimulated by an inflammatory environment. 
Table 5. Secretome of N-TEC and A-TEC upon exposure to Low Inflammation and medium conditioned by OA-
Synovial cells (OA-Syn_CM). Cytokine concentrations (in pg/ml) measured in the supernatants of nasal or articular 
chondrocyte-based tissues (N-TEC/A-TEC) when cultured in basal medium (CTR) or in the OA-simulating conditions 
Low Inflammation and OA-Syn_CM. Values represented as the mean ±SD of n = 4 AC/NC matched donors. n.d. 
denotes not detected levels or values < 0.1. * indicates significant difference from CTR at the corresponding condition 
and $ significant difference between N-TEC and A-TEC at same condition. Differences assess by Mann-Whitney-U 
analyses. P < 0.05 considered significant.  
  N-TEC A-TECC 
 CTR +Low Inflammation +OA-Syn_CM CTR +Low Inflammation +OA-Syn_CM 
MIP1α/CCL3 n.d. 308.8 ±175.6* 385.7 ±27.3* n.d. 341.5 ±110.8* 392.6 ±37.2* 
MIP1β/CCL4 42.6 ±70.5 550.6 ±157.2* 811.2 ±61.9* 37.6 ±79.8 516.6 ±233.6* 803.1 ±52.7* 
MCP1/CCL2 1244.4 ±662.7 12235.1 ±10318.7* 15934.0 ±3135.4* 876.0 ±964.4 13312.9 ±11768.5* 14734.6 ±2371.7* 
IP10/CXCL10 0.7 ±2.0$ 24.2 ±19.6* 66.3 ±4.7* 6.3 ±7.1$ 94.6 ±33.9* 73.5 ±6.9* 
GCSF n.d. 136.9 ±273.9 n.d. n.d. 29.5 ±34.7 n.d. 
Eotaxin/CCL11 n.d. n.d. n.d. n.d. 8.8 ±17.7 n.d. 
IL1β n.d. 4.7 ±6.5 n.d. n.d. 3.1 ±3.59 n.d. 
IL4 107.9 ±61.0 419.1 ±85.4* 472.3 ±20.6* 65.0 ±82.4 393.9 ±152.2* 486.3 ±18.3* 
IL6 94.5 ±113.7 9985.0 ±12243.7* 7864.7 ±481.6* 32.6 ±33.6 3743.7 ±3053.4* 8019.9 ±535.7* 
IL7 0.1 ±0.2 15.8 ±8.3* 22.0 ±1.7* 0.1 ±0.3 15.2 ±11.6* 22.1 ±0.9* 
IL8/CXCL8 125.8 ±196.4 20918.6 ±25526.5* 2028.0 ±180.7* 61.7 ±103.6 24684.2 ±30265.7* 2061.6 ±164.7* 
IL10 n.d. 2.1 ±1.5 2.9 ±0.5* n.d. 2.3 ±2.7 4.4 ±1.0* 
IL12 n.d. 157.6 ±99.6* 212.5 ±28.7* n.d. 133.3 ±145.0 211.8 ±21.9* 
IL13 n.d. 442.4 ±391.8 795.9 ±76.1* n.d. 496.5 ±573.6 843.3 ±108.7* 
IL17 n.d. 5.0 ±5.2* 5.8 ±1.6* n.d. 4.9 ±5.66 6.8 ±2.8* 
IL1RA 10.1 ±18.7 263.4 ±116.5* 952.1 ±116.1* 8.7 ±18.8 245.1 ±149.4* 964.6 ±140.4* 
TNFα n.d. 95.1 ±73.7* 23.1 ±2.9* n.d. 91.1 ±69.0* 22.1 ±1.6* 
IFNγ n.d. 25.5 ±30.1 39.7 ±28.8 n.d. 33.4 ±38.6 48.3 ±20.6* 
RANTES/CCL5 28.8 ±17.8 60.4 ±15.1* 73.1 ±5.4* 52.1 ±40.2 208.9 ±115.0*$ 177.8 ±123.5 
MMP3 35301.3±28555.2 64304.8 ±33620.0 30817.6 ±16311.4 21291.7 ±21093.4 97224.8 ±42922.2 17367.9 ±2660.9 
MMP13 n.d. 161.5 ±323.0 n.d. 104.4 ±159.3 217.4 ±343.0 n.d. 
 
 
 
52 
4.1.3 Discussion		
Results described in this section regarding the responses of nasal chondrocyte-based engineered 
constructs (N-TEC) to different OA-inflammatory conditions, evidenced the capacity of these 
tissues to preserve the cartilaginous matrix when exposed to inflammatory cues associated with an 
OA-environment. In particular, the histological quality of N-TEC was better preserved, as compare 
to A-TEC, regarding the content of typical ECM molecules such as GAG and type II collagen (Fig 
4C, 6C). The superior capacity of N-TEC to withstand such conditions, was further supported by 
the findings of a non-affected expression profile upon exposure to the different assessed conditions, 
whereas AC-based tissues had higher levels of inflammatory and catabolic genes such as IL6 and 
MMP13, in comparison to N-TEC (Fig. 5B) and CTR condition (Fig. 7A).  
In additional analysis, detection of such markers at protein level evidenced that both N-TEC and 
A-TEC undergo a similar modulation on their secretory profiles upon inflammation. The only 
differentially modulated factor was RANTES, secreted with a significantly higher concentration 
by A-TEC, as compared N-TEC, in the condition of Low Inflammation. Thus, favoring the 
indications of better performance for NC-engineered tissues.     
Overall, the here generated data coincides with previous studies comparing the chondrogenic 
capacity of nasal and articular chondrocytes, regarding the higher content of GAG and type II 
collagen in NC-based tissues that in A-TEC at control conditions. In those studies, GAG loss has 
been also reported as result of the short IL1β stimulus (3d) or a prolonged exposure (up to 21d) to 
the same cytokine cocktail hence used (IL1β, IL6, and TNFa), but in a medium with glucose 
deprivation and under hypoxic conditions (154, 242).  Conversely, in this thesis no significant up-
regulation of catabolic factors such as MMP13 was observed neither in N-TEC nor in A-TEC, as 
reported when more ‘acute’ inflammatory conditions were used (i.e., high dose, short exposure to 
IL1β). Such distinctive response could be presumably attributed to the differential role that diverse 
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levels of inflammation and exposure times might play in the promotion of a catabolic environment 
(164).  
As a limitation for the interpretation of the current data, the GAG measurement - as single 
parameter - was found non-conclusive for assessing the responses of engineered tissues to the 
conditions here tested. This, considering that although the majority of inflammatory conditions 
caused a decreased GAG content in both N-TEC and A-TEC, the same effect was observed with 
the medium used as control (CTR). Such observations prevented a clean discrimination of the effect 
caused by the used factors (cytokines or CM), among other potential detrimental conditions such 
as the presence of serum (244) and the absence of TGF-β. The supplementation with serum could 
not be avoided due to its relevance for the culture of OA-Syn (from which CM was derived), and 
the TGF-β was not included in order to have conditions better representing those used for the 
clinical manufacturing of N-TEC (157).  
Complementary analysis for better understanding of the differential nature between nasal and 
articular chondrocytes, as well as the superior potential of NC for clinical applications, might 
include a comparative transcriptomic analysis of both cell types (ongoing in our group). This will 
support the elucidation of innate cell features, such as differential expression levels of 
inflammatory (Data included in submitted manuscript), anabolic and catabolic factors (to be further 
investigated). In order to better characterize the responses of N-TEC and A-TEC to the 
implemented OA simulating conditions, as well as to understand more broadly the mechanisms 
underlying disease progression or recovery, the study of cellular processes - other than the 
metabolic/inflammatory ones- could be of critical relevance. Such additional outlooks could be 
focused on the roles of senescence, autophagy, apoptosis and oxidative stresses (245–247). 
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 Aim	II:	Modulatory	effects	of	N-TEC	on	the	transcriptomic	and	secretory	
profiles	of	osteoarthritic	cells	and	tissues	
4.2.1 Introduction	
In the osteoarthritic knee, the increased concentrations of circulating inflammatory and catabolic 
molecules is a well-established feature of the disease, when compared to healthy condition (174). 
Considered a pathology of the joint as a whole (162), those factors can be secreted by the 
chondrocytes themselves (248, 249) and/or by the cells present in the adjacent tissues such as the 
synovial membrane (250, 251) and subchondral bone (175, 218). Consequently, after determining 
the effects that those mediators exert on nasal chondrocytes - in the form of engineered cartilage - 
(Aim I), it was imperative to evaluate the modulatory effects that N-TEC could have in the 
production of the mentioned molecules, in order to understand the implications of a 
multidirectional interaction between the different cell/tissue types within the joint.  
With that intention, the aim was to determine the effects of N-TEC secreted factors on the 
phenotype of osteoarthritic articular chondrocytes (OA-AC), synoviocytes (OA-Syn) and 
osteochodral tissue explants (OA-OC). Pro-inflammatory and catabolic profiles of the chosen 
models have been previously established through immunodetection and cytokine profiling for OA-
Syn (171, 252), as well as with protein quantification or gene expression analysis for OA-OC 
explants or osteoblasts (OB) isolated from an OA joint (175, 193). In the case of OA-AC, their 
phenotype have been characterized as unstable in terms of de-differentiation, reduced expression 
of anabolic molecules, and increased secretion of catabolic and inflammatory factors OA-OA (174, 
249, 253). 
Attenuation of the described OA-related phenotypes have been also reported in OA-Syn by 
secreted factors from adipose-derived stromal cells (252), in OA-OC by inhibition of the TGF-b 
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pathway (193) and in OA-AC by stimulation with a chemical agent, in a scaffold-based culture 
system (219).  
Although the capacity of nasal chondrocytes to withstand degenerative-simulating conditions have 
been demonstrated in different contexts (Aim I, (242)), their potential anti-inflammatory/anti-
catabolic properties have not been yet investigated. This chapter constitutes the first approach in 
that direction - in the frame of osteoarthritis -, and summarizes the findings of the afore described 
experimental models.  
4.2.2 Results	
4.2.2.1 Modulation	of	the	inflammatory/catabolic	profile	of	osteoarthritic	articular	
chondrocytes	by	nasal	chondrocytes-secreted	factors	
Addressing whether nasal chondrocytes - as the therapeutic agent explored in this manuscript - 
could have an anti-inflammatory/catabolic effect on OA-AC; 3D aggregates of these cells were 
exposed to media conditioned by nasal chondrocytes (N-TEC_CM), at micro and macroscales, 
(section 7.3.1.3) or to CTR. The conditioned medium from healthy articular chondrocytes (A-
TEC_CM) was used (i) as reference cell from the targeted tissue (i.e., articular cartilage) and (ii) 
to assess whether effects were specific to the nasal origin of the cells, or a general chondrocyte-
related feature. Modulatory effects of the different conditions were then determined by qRT-PCR, 
immunofluorescence and/or protein quantification according to the specific model.  
4.2.2.1.1 Optimization	of	 experimental	 conditions	 for	 the	 exposure	of	OA-AC	 to	 conditioned	
media		
It was previously shown that microaggregates (of about 100cells/unit) cultured in a microfluidic 
device  have a more uniform and reproducible response to continuously perfused stimuli (254). In 
the system here described, the stimulus consisted of the perfusion of N-TEC or A-TEC derived 
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conditioned media. Parallel studies indicated that the culture with 80% of N-TEC_CM during 7 
days post-differentiation was capable of maintaining the chondrogenic ECM, as assessed by 
immune-detection of type II collagen, ans sufficient to reduce the production of catabolic and 
factors inflammatory by OA-AC,  such as the MMP13 at protein level (Fig. 8A) and ADAMTS5, 
MMP13 and IL8 at mRNA level (Fig. 8B) (255). For this reason, stimulation for 7d and 80% CM 
were the chosen conditions for the entire setup.  
4.2.2.1.2 N-TEC	secreted	factors	down	regulate	the	production	of	inflammatory	and	catabolic	
factors	in	OA-AC		
To evaluate the responses of OA-AC to the medium conditioned by N-TEC and A-TEC (N-
TEC_CM/A-TEC_CM), NC and AC were isolated, expanded, chondrogenically differentiated and 
used to produce the conditioned medium. In parallel, AC form OA donors (OA-AC) were also 
isolated and used to form 3D aggregates that were further exposed to CTR or to conditioned media 
in two different culture systems; at micro and macro scales (Fig. 9A). 
4.2.2.1.2.1 Microscale 
After exposure to experimental conditions, gene expression analysis of OA-AC exposed to N-
TEC_CM had a significant reduction in transcription levels of the inflammatory cytokine IL8 and 
the catabolic factor MMP13 as compared to CTR (basic culture medium), with the same trend 
followed by the aggrecanase enzyme ADAMTS5 (P =0.0609). This reduction did not occur in the 
presence of A-TEC_CM (Fig. 9B). The anti-catabolic effect on MMP13 reduction was further 
ratified at protein level, with a low detection of the enzyme in N-TEC_CM treated microaggregates, 
as compared to CTR or A-TEC_CM treated OA-AC (Fig. 9C). Due to the scale, no material for 
additional analysis could be harvested from this culture system. 
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Figure 8. Modulation of catabolic, anabolic and inflammatory markers in OA-AC by concentrations of N-
TEC_CM. (A) Immuno-fluorescent detection of the catabolic marker MMP13 and the anabolic type II collagen, in 
3D aggregates of osteoarthritic articular chondrocytes (OA-AC) after exposure to different concentrations of N-
TEC_CM - medium conditioned by tissue engineered cartilage generated with nasal chondrocytes – (left). 
Quantification of the staining for MMP13 presented on the right. (B) OA-AC expression levels for the pro-
inflammatory marker IL8 and the catabolic MMP13 and ADAMTS5, after N-TEC_CM treatment. Green square 
indicates the concentration of 80% CM, in which levels of catabolic and inflammatory factors were lower while still 
preserving some type II collagen. 
4.2.2.1.2.2 Macroscale 
In order to perform a broader characterization than in the micro-system, a standard macroaggregate 
culture (2.5x105 cells/unit) was implemented (256). In this latest setup, and similarly to what was 
observed in the microaggregates, the culture of OA-AC with N-TEC secreted factors caused a 
significant reduction in the mRNA levels of MMP13 and ADAMTS5, while  IL8 levels remained at 
the same level than CTR treated macroaggregates. Instead, culture of OA-AC with A-TEC_CM 
significantly increased the production of IL8 transcripts. In addition, the modulation of IL6 mRNA 
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was assessed in this model, being not significantly regulated by any of the tested conditions (Fig. 
9D). Detection of MMP13 by immunofluorescence demonstrated the absence of this molecule in 
the OA-AC treated with N-TEC_CM, whereas it was present in the macroaggregates exposed to 
both CTR and A-TEC_CM (Fig 9E).  
To quantify the responses at protein level, factors secreted by OA-AC when exposed to N-
TEC_CM or A-TEC_CM were measured in the culture supernatants and compared to expected 
concentrations (calculated as the sum of the amount secreted by OA-AC at CTR condition plus the 
amount measured in the N-TEC_CM or A-TEC_CM). This assessment revealed that neither nasal 
or healthy articular chondrocytes conditioned media could modulate the secretion of the majority 
of the factors such as MIP1α, MIP1β, IP10, IL1β, IL7, IL10, IL13, IL1Ra, TNFα, RANTES, 
MMP3 and MMP13.  Among the whole panel assessed, the secretion of IL12 was suppressed by 
N-TEC_CM, IP10 by A-TEC_CM and INF-g by both N-TEC/A-TEC_CM.  Up-regulation was 
only observed in the presence of A-TEC_CM for the cytokines MCP1, IL4, IL6 and IL8 (Table 6). 
The observed modulatory effects on factors classically studied by their relevance in OA (IL1β, IL6, 
IL8, TNFα and RANTES) are illustrated in Fig. 9F.  
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Figure 9. Modulatory effects of N-TEC and A-TEC secreted factors on the phenotype of osteoarthritic articular 
chondrocytes (OA-AC). (A) Schematic representation of experimental design. (B) Expression levels of 
microaggregates generated with OA-AC (n = 2 donors) for selected factors, following exposure to CTR or to medium 
conditioned by N-TEC (N-TEC_CM) and A-TEC (A-TEC_CM) (both pooled from n=5 donors). (C) 
Immunofluorescent detection of MMP13 in micro-aggregates. (D) Expression levels of OA-AC macroaggregates (n= 
2 donors) for selected factors, following exposure to CTR and N-TEC/A-TEC_CM. (E) Immunofluorescent detection 
of MMP13 in OA-AC macroaggregates. (F) Expected (sum of values for OA-AC (n = 3 donors) in CTR plus amounts 
quantified in N-TEC_CM or A-TEC_CM) and Measured (values of OA-AC cultured in N-TEC_CM or A-TEC_CM) 
concentrations of selected factors quantified in culture supernatants. n.d. denotes not detected levels or values < 0.1. 
Differences assess by Mann-Whitney-U analyses. P < 0.05 considered significant.  
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Table 6. Secretome of OA-AC upon exposure to N-TEC and A-TEC secreted factors. Cytokine concentrations (in 
pg/ml) measured in the supernatants of osteoarthritic chondrocytes (OA-AC) when cultured in CTR or in N-TEC or 
A-TEC conditioned medium (N-TEC/A-TEC_CM). Values represented as the mean ±SD of n = 3 OA-AC donors and 
n = 1 CM (pooled from 5 donors). n.d. denotes not detected levels or values < 0.1. * indicates a significant difference 
between measured and expected values, assessed by Mann-Whitney U test. Unilateral P ≤ 0.05 considered significant. 
 
4.2.2.2 Modulation	of	the	inflammatory	profile	of	osteoarthritic	synovial	cells	by	
nasal	chondrocytes	secreted	factors	
Synovial cells are the typically reported source of inflammatory factors in an OA joint (160). 
Therefore, after assessing the modulatory effects of N-TEC_CM on OA-AC, it was important to 
determine the potential of N-TEC secreted factors to down-regulate the inflammatory phenotype 
of this cell type. For this purpose, cells from the synovial tissue of osteoarthritic joints (OA-Syn) 
were isolated and cultured in the presence of N-TEC_CM, A-TEC_CM or CTR (section 7.3.1.5) 
(Fig. 10A). Regulatory effects of these conditions were then assessed by quantification of the 
cytokines in the resulting culture supernatants, as well as by qRT-PCR.  
MIP1α/CCL3 107.1 ± 95.5 73.8 ± 127.8
MIP1β/CCL4 53.6 ± 64.0 130.9 ± 196.2
MCP-1/CCL2 136.6 ± 102.9 78.9 ± 44.8 728.7 ± 633.3 865.3 ± 633.3 1296.9 ± 1166.0 807.6 ± 633.3 2760.4 ± 2242.1*
IP10/CXCL10 1.6 ± 3.6 1.6 ± 3.6
GCSF
Eotaxin/CCL11
IL1β 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1
IL4 0.1 ± 0.2 0.1 ± 0.1 67.0 ± 58.2 67.1 ± 58.2 107.9 ± 95.7 67.1 ± 58.2 193.7 ± 113.4*
IL6 32.0 ± 33.5 69.6 ± 53.3 27.8 ± 32.8 59.8 ± 32.8 91.0 ± 78.1 97.4 ± 32.8 337.0 ± 77.8*
IL7 2.1 ± 3.6
IL8/CXCL8 9.6 ± 7.5 11.5 ± 8.7 60.8 ± 47.9 70.4 ± 47.9 88.3 ± 78.8 72.3 ± 47.9 171.8 ± 22.3*
IL10 0.1 ± 0.2 0.1 ± 0.2
IL12 20.5 ± 13.0 19.0 ± 12.0 20.5 ± 13.0 19.0 ± 12.0 10.9 ± 18.9
IL13
IL17
IL1Ra 0.2 ± 0.5 12.4 ± 21.5 0.2 ± 0.5 43.5 ± 75.3
TNFα 0.3 ± 0.6 0.8 ± 1.1 0.3 ± 0.6 0.8 ± 1.1 2.9 ± 5.0
IFNϒ 3.1 ± 4.3 4.1 ± 6.4 3.1 ± 4.3 4.1 ± 6.4
RANTES/CCL5 48.0 ± 44.2 24.1 ± 14.2 24.1 ± 14.2 25.8 ± 23.4 72.2 ± 14.2 49.8 ± 30.6
MMP3 22407.4 ± 14682.5 22407.4 ± 14682.5 20144.4 ± 15626.0 22407.4 ± 14682.5 32826.8 ± 10275.6
MMP13 62.4 ± 27.9 4981.4 ± 5034.9 62.4 ± 27.9 37.0 ± 64.1 4981.4 ± 5034.9 187.3 ± 324.5
ADAMTS5
Single cells OA-AC+N-TEC_CM OA-AC+A-TEC_CM
N-TEC_CM A-TEC_CM OA-AC Expected Measured Expected Measured
n.d. n.d. n.d. n.d. n.d.
n.d. n.d. n.d. n.d. n.d.
n.d. n.d. n.d. n.d. n.d.*
n.d. n.d.
n.d. n.d. n.d. n.d. n.d. n.d. n.d.
n.d. n.d. n.d. n.d. n.d.
n.d. n.d. n.d. n.d. n.d.
n.d. n.d.*
n.d. n.d.* n.d.*
n.d.
n.d. n.d. n.d.* n.d. n.d.
n.d.
n.d. n.d. n.d. n.d. n.d. n.d. n.d.
n.d. n.d. n.d. n.d. n.d. n.d.
n.d. n.d. n.d.
n.d. n.d.*
n.d. n.d.
n.d.*
n.d.
n.d. n.d.
n.d.
n.d. n.d. n.d. n.d. n.d.
n.d. n.d.*
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4.2.2.2.1 Optimization	of	experimental	conditions	for	the	exposure	of	OA-Syn	to	conditioned	
media	
Comparison of the secretory profile of OA-Syn cultured during 2 or 7 days showed that all the 
inflammatory related molecules measured (MIP1α, MIP1β, MCP1, IP10, IL1β, IL6, IL7, IL8, 
IL10, IL12, IL1RA, TNFα, INFγ and RANTES) were already secreted into the supernatant by day 
2. The prolongation of the culture conditions (up to 7 days) caused either a drop or a suppression 
of the majority of the factors, being MCP1and IL6 the only factors whose concentration slightly 
increased at the latest measured time (Fig. 10B). For this reason, the duration for exposing OA-
Syn to the conditioned media or CTR was set at 2 days.  
In order to determine the appropriate concentration of CM effectively modulating the secretory 
profile of OA-Syn, this OA cell type was exposed to 100, 50 or 25% (v/v in CTR medium) of N-
TEC_CM or CTR (0% CM), to then measure the concentrations of the targeted cytokines (same 
panel than for the timing comparison).  In these conditions, the concentrations of 100 and 50% 
reduced the secreted levels of MIP1α, MIP1β, MCP1, IL1β, IL6, IL7, IL8, INFγ and RANTES in 
OA-Syn, as compared to the concentration of 25% and the basal secreted levels at 0%. Those same 
higher concentrations suppressed the production of IP10, IL1RA and TNFα.  Only for IL7 and 
IL10 - out of the fourteen factors measured - the concentration levels were lower at the condition 
of 25% than it at least one of the other concentrations of N-TEC_CM. No relevant differences in 
the effect were detected between 100% and 50% (Fig. 10C), therefore CM was diluted 1:1 with 
CTR medium for all forthcoming experiments.    
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Figure 10. Secretory profile of OA-Syn and modulation by culture time and exposure to N-TEC_CM. (A) 
Schematic representation of experimental design. (B) Secreted concentrations of selected factors by osteoarthritic 
synovial cells (OA-Syn) in different culture times and (C) when exposed to different concentrations of medium 
conditioned by N-TEC (N-TEC_CM). Values corresponding to measurements in 1 (out of 2) used OA-Syn donors. 
Dashed line indicates the secreted values by OA-Syn in CTR (0% CM). 
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4.2.2.2.2 N-TEC	secreted	factors	down	regulate	the	production	of	inflammatory	and	catabolic	
factors	in	OA-Syn		
Once experimental conditions (2days of exposure to 50% CM) were established, factors secreted 
by OA-Syn when cultured with N-TEC_CM or A-TEC_CM were measured in the supernatants 
and compared to expected concentrations (calculated as the sum of the amount secreted by OA-
Syn at CTR plus the amount measured in the N-TEC_CM or A-TEC_CM). Quantification revealed 
that the majority of the factors were similarly modulated in the presence of both N-TEC and A-
TEC_CM, by significantly decreasing levels of MIP1α, MIP1β, MCP1, IP10, IL1β, IL8, IL17 
IL1RA and RANTES, while increasing production of IL10, IL12 and IL13. Differentially, only the 
culture with N-TEC_CM caused a significant downregulation of IL6 and TNFα (P= 0.025 and P= 
0.028 respectively). Modulation of selected factors (IL1β, IL6, IL8, TNFα, RANTES) is illustrated 
in Fig. 11A, and the measured values for the extended panel presented in Table 7. In the same 
setup, gene expression analysis confirmed the significant reduction of IL8 levels only for the N-
TEC_CM treated OA-Syn. Nasal chondrocytes secreted factors additionally downregulated the 
expression of MMP13 and ADAMTS5, as compared to control condition and in line with the 
findings for OA_AC. This modulation did not occur in the presence of A-TEC_CM (Fig. 11B). 
4.2.2.3 Modulation	of	the	secretory	profile	of	osteoarthritic	osteochondral	explants	
by	nasal	chondrocyte	secreted	factors		
In addition to OA-AC and OA-Syn, cells present in the subchondral bone of an OA joint also 
contribute to the increased circulating concentrations of inflammatory and catabolic mediators 
(161). For this reason, it was of complementary interest to evaluate the effects of N-TEC released 
factors on the secretory profile of osteoarthritic-osteochondral explants (OA-OC). Consequently, 
similarly to the setups implemented for OA-AC/Syn, in this experimental setting pieces of OA-OC 
tissues were isolated and cultured in the presence N-TEC_CM, A-TEC_CM or CTR (Fig. 12A). 
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Modulatory effects on selected factors were assessed by histological characterization and protein 
quantification. Duration of the exposures was set at 7days according to previous studies where 
these ex-vivo osteochondral explants have been used (193). Concentration for chondrocyte 
conditioned media was chosen accordingly to the one we found effective for modulating the OA-
AC profile (at 80%).  
 
Figure 11. Modulatory effects of N-TEC and A-TEC secreted factors on the phenotype of osteoarthritic synovial 
cells (OA-Syn). (A) Concentrations of selected factors secreted by OA-Syn (n = 6 donors) after exposure to CTR or 
to medium conditioned by N-TEC or A-TEC (A-TEC_CM) (n = 4 donors each). Values represented as the mean ±SD 
of Expected (sum of values for OA-syn in CTR plus amounts quantified in N-TEC_CM or A-TEC_CM) and Measured 
(values of OA-Syn cultured in N-TEC_CM or A-TEC_CM) concentrations quantified in culture supernatants. (B) 
Expression levels of selected genes by OA-Syn for the different experimental conditions. 12 experimental replicates 
measured per condition. n.d. denotes not detected levels or values < 0.1. * indicates a significant difference between 
measured and expected values, assessed by Mann-Whitney U test. Unilateral P ≤ 0.05 considered significant. 
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Table 7. Secretome of OA-Syn upon exposure to N-TEC and A-TEC secreted factors. Cytokine concentrations 
(in pg/ml) measured in the supernatants of osteoarthritic synovial cells (OA-Syn) when cultured in CTR or in N-TEC 
or A-TEC conditioned medium (N-TEC/A-TEC_CM). Values represented as the mean ±SD of 12 experimental 
replicates for n = 3 Syn donors, randomly combined with n = 4 CM donors. n.d. denotes not detected levels or values 
< 0.1. * indicates a significant difference between measured and expected values, assessed by Mann-Whitney U test. 
Unilateral P < 0.05 considered significant. 
 
4.2.2.3.1 N-TEC	secreted	factors	down	regulate	the	production	of	inflammatory	and	catabolic	
factors	in	OA-OC	tissues	
After exposure to experimental conditions, secreted levels of MIP1α, MIP1β, GCSF, IL6, IL10, 
IL1Ra, TNFα, RANTES, MMP13, ADAMTS4 and ADAMTS5 were measured in the culture 
supernatants and compared to expected concentrations (calculated as the sum of the amount 
secreted by OA-AC at CTR condition plus the amount measured in the N-TEC or A-TEC_CM). 
Such quantification revealed that both conditioned media had similar effect on the secretome of 
OA-OC with no modulation on MIP1β, GCSF, IL6 and ADAMTS5, and a significant down 
regulation in levels of MIP1α, IL10, IL1Ra, TNFα, MMP3 and ADAMTS4.  RANTES was the 
MIP1α/CCL3 433.1 ± 60.3 433.1 ± 60.3 107.7 ± 137.1* 433.1 ± 60.3 50.4 ± 60.4*
MIP1β/CCL4 2859.6 ± 287.7 2859.6 ± 287.7 1413.9 ± 644.3* 2859.6 ± 287.7 1308.7 ± 529.1*
MCP-1/CCL2 170.8 ± 79.7 98.6 ± 8.9 662.0 ± 126.8 786.9 ± 139.8 569.5 ± 99.6* 714.7 ± 105.9 528.5 ± 62.8*
IP10/CXCL10 2.0 ± 4.0 9626.4 ± 8600.6 9626.4 ± 8600.6 3358.4 ± 5260.0* 9628.5 ± 8602.0 2002.9 ± 2332.9*
GCSF 3.0 ± 1.4 3.0 ± 1.4 7.2 ± 7.2 3.0 ± 1.4 4.8 ± 5.6
Eotaxin/CCL11 23.6 ± 13.5 23.6 ± 13.5 42.8 ± 53.3 23.6 ± 13.5 34.4 ± 45.4
IL1β 0.1 ± 0.1 0.1 ± 0.1 15.8 ± 2.6 16.6 ± 2.0 5.9 ± 5.3* 16.6 ± 2.0 3.3 ± 3.1*
IL4 0.2 ± 0.2 0.1 ± 0.1 1.9 ± 1.1 2.3 ± 0.9 1.9 ± 0.76* 2.3 ± 0.9 1.7 ± 0.5*
IL6 40.0 ± 32.8 87.0 ± 42.0 5070.8 ± 2665.4 5629.4 ± 2262.4 3759.3 ± 1913.0* 5673.7 ± 2267.7 5141.4 ± 1292.2
IL7 16.9 ± 8.7 16.9 ± 8.7 15.9 ± 11.6 16.9 ± 8.7 14.2 ± 5.2
IL8/CXCL8 12.0 ± 6.0 15.4 ± 4.9 3538.6 ± 399.2 3532.9 ± 392.1 1554.7 ± 925.4* 3533.3 ± 391.7 1354.5 ± 667.3*
IL10 0.2 ± 0.2 2.9 ± 0.8 3.0 ± 0.7 7.7 ± 2.9* 2.9 ± 0.8 6.7 ± 2.6*
IL12 25.6 ± 7.2 23.7 ± 6.4 22.8 ± 14.2 51.1 ± 9.6 67.5 ± 11.2* 49.6 ± 11.3 76.4 ± 12.5*
IL13 0.5 ± 0.2 0.5 ± 0.2 1.0 ± 0.5* 0.5 ± 0.2 1.1 ± 0.5*
IL17 21.2 ± 10.3 21.2 ± 10.3 14.1 ± 8.6* 21.2 ± 10.3 11.0 ± 5.8*
IL1RA 109.5 ± 73.5 109.5 ± 73.5 49.0 ± 44.8* 109.5 ± 73.5 56.4 ± 54.2*
TNFα 0.3 ± 0.7 1.0 ± 1.1 11.1 ± 6.4 13.3 ± 5.3 8.5 ± 6.3* 13.9 ± 5.7 12.0 ± 5.8
IFNϒ 3.8 ± 4.6 5.2 ± 6.9 75.9 ± 48.7 93.6 ± 40.0 80.2 ± 38.9* 95.0 ± 41.2 76.6 ± 32.9
RANTES/CCL5 60.1 ± 40.5 548.2 ± 331.4 548.2 ± 331.4 114.6 ± 73.6* 601.3 ± 343.8 160.1 ± 157.3*
Single cells OA-Syn+N-TEC_CM OA-Syn+A-TEC_CM
N-TEC_CM A-TEC_CM OA-Syn Expected Measured Expected Measured
n.d n.d
n.d n.d
n.d n.d
n.d
n.d n.d
n.d n.d
n.d n.d
n.d
n.d n.d
n.d n.d
n.d
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only factor differentially affected by nasal or articular chondrocytes-derived conditioned medium, 
being significantly downregulated just in the presence of A-TEC_CM (Table 8).  
No modulation on extracellular composition was evidence by immunohistochemical detection of 
GAG and type-II/I Collagens (Fig. 12B,C).  
 
Figure 12. Modulatory effects of N-TEC and A-TEC secreted factors on the phenotype of osteoarthritic 
osteochondral plugs (OA-OC). (A) Schematic representation of experimental design. (B) Safranin-O staining and 
(C) type II collagen immunohistochemical detection, for OA-OC tissues (n = 2 donors) upon exposure to CTR or 
medium conditioned by N-TEC (N-TEC_CM) and A-TEC (A-TEC_CM) (n = 2 donors). Scale bar = 1000 µm. 
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Table 8. Secretome of OA-OC upon exposure to N-TEC and A-TEC secreted factors. Cytokine concentrations (in 
pg/ml for CM§ and in pg/mg for OA-OC and combinations¥) measured in the supernatants of osteoarthritic 
osteochondral tissues (OA-OC) when cultured in CTR, N-TEC or A-TEC conditioned medium (N-TEC/A-TEC_CM). 
Values represented as the mean ±SD of 4 experimental replicates for n= 2 OA-OC donors combined with n= 2 CM 
donors. n.d. denotes not detected levels or values < 0.1. * indicates a significant difference between measured and 
expected values, assessed by Mann-Whitney U test. Unilateral P ≤ 0.05 considered significant. 
  Controls OA-OC+N-TEC_CM¥ OA-OC+A-TEC_CM¥ 
  NTEC-CM§ ATEC-CM§ OA-OC¥ Expected Measured Expected Measured 
MIP1α n.d. n.d. 15.0 ± 4.9 20.1 ± 8.1 18.8 ± 8.0* 19.5 ± 6.4 19.2 ± 6.0* 
MIP1β 18.9 ± 1.1 26.7 ± 10.3 0.7 ± 0.2 1.2 ± 0.4 7.9 ± 13.1 1.3 ± 0.3 3.0 ± 3.8 
GCSF 3.6 ± 0.3 5.1 ± 1.7 0.1 ± 0.0 0.2 ± 0.1 0.1 ± 0.1 0.2 ± 0.1 0.1 ± 0.0 
IL6 40.0 ± 33.5 87.0 ± 53.3 90.3 ± 34.9 123.0 ± 41.9 127.2 ± 67.5 120.5 ± 32.3 111.8 ± 50.2 
IL10 22.9 ± 4.1 30.6 ± 7.7 0.6 ± 0.2 1.1 ± 0.4 0.7 ± 0.3* 1.1 ± 0.4 0.7 ± 0.2* 
IL1Ra 242.0 ± 14.3 320.3 ± 51.1 5.4 ± 1.7 10.3 ± 4.1 7.2 ± 3.9* 11.0 ± 3.6 6.6 ± 1.9* 
TNFα 9.2 ± 1.6 42.6 ± 20.3 0.4 ± 0.1 0.7 ± 0.3 0.6 ± 0.4* 1.1 ± 0.4 0.6 ± 0.2* 
RANTES n.d. 0.0 ± 0.0 25.3 ± 21.4 35.0 ± 23.1 28.0 ± 45.9 33.7 ± 20.6 10.9 ± 15.0* 
MMP3 22378.7 ± 3487.7 46495.3 ± 31087.0 1770.2 ± 402.5 2640.3 ± 876.1 1592.5 ± 726.0* 2866.9 ± 736.2 1736.7 ± 518.4* 
ADAMTS4 6.0 ± 9.5 7.5 ± 11.2 0.3 ± 0.2 0.6 ± 0.2 0.1 ± 0.1* 0.7 ± 0.2 0.2 ± 0.1* 
ADAMTS5 n.d. n.d. 3.2 ± 3.7 5.4 ± 2.2 5.3 ± 5.9 6.3 ± 3.7 6.3 ± 5.4 
 
4.2.3 Discussion	
The findings described above demonstrate that factors released by engineered cartilaginous tissues 
generated with adult nasal chondrocytes (N-TEC), can attenuate the inflammatory and catabolic 
profile of osteoarthritic (OA) cells/tissues in a target-specific manner, inducing differential 
responses on each of the experimental setups.  
Although the main interest of this investigation resides on the potential use of N-TEC for the 
treatment of OA lesions, the secreted factors of A-TEC were studied in addition, resulting on a 
similar modulation of the targeted profiles in most of the cases. However differential modulation 
of the more typically OA-related factors was evidenced as positive only for the N-TEC_CM, 
regarding exclusive significant downregulation of IL8, MMP13 and ADAMTS5 gene expression 
levels in both OA-AC and OA-Syn, as well as a significantly reduced secreted concentrations of 
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IL6 and TNFα in OA-Syn (Fig. 9,11). This differential effect among N-TEC and A-TEC secreted 
factors, was additionally supported by the increased production of pro-inflammatory factors by 
OA-AC, exclusively caused by the presence of A-TEC_CM,  as observed for IL8 at mRNA level 
(Fig. 9) and different other cytokines at protein level - including IL8 and IL6 - (Table 6).  
It is presumed that the anti-inflammatory/catabolic properties of showed by N-TEC secreted 
factors, in combination with the chondrogenic matrix maintenance under degenerative-simulating 
conditions previously demonstrated (section 4.1, (242)), may be beneficial for the long-term 
performance of the graft. However, further studies are needed in order to understand the 
contribution of these two features to a potential delay in the progression of the disease, a structural 
amelioration of the joint, or a presumable restoration of cartilage homeostasis.  Considering these 
last two parameters, further characterization of OA-AC tissues may give additional information 
regarding the maintenance/restoration of ECM composition in the presence of N-TEC_CM. The 
study of further OA features, other than the here investigated inflammatory and catabolic 
components, could also complement the assessment of beneficial effects for example, if 
amelioration of senescent traits or impaired autophagy are found (257–259). 
For an in depth understanding of the potential disease modifying properties of N-TEC released 
factors, further studies would be required to investigate which components of the N-TEC 
secretome, including soluble molecules and extracellular vesicles, might be the triggers of the 
observed responses. Moreover, whether the pre-treatment of NC with specific molecules could 
boost such effects, as demonstrated for MSC in the context of a different pathology (260). 
Nonetheless, one of the main constraints for estimating the implications of the here described 
findings in a more physiological scenario, lies on the incomplete knowledge of underlying 
mechanisms, limiting the understanding of features that a relevant/standard model should involve. 
Among the ones here used, the pro-inflammatory component could be recapitulated mostly by 
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osteoarthritic synovial cells and the osteochondral explants. Those OA specimens were confirmed 
as the major contributors to the circulating levels of inflammatory cytokines, whereas most of the 
factors were not detected in the chondrocytes, either healthy (nasal or articular) or diseased (Tables 
5, 6). Besides, secreted levels of the typically OA-associated factors IL1β, IL6, IL8, TNFα and 
RANTES were similar for all chondrocytes, and values of lower magnitude than in the OA-Syn 
and OA-OC (Tables 7, 8).  
Collected data also reflects a wide variability between donors for all sources of OA specimens. 
This, in coherence with findings from other studies, with even higher number of experimental 
samples. In those, such variability is correlated with diverse the severity of pathological symptoms 
(171, 174, 252). Higher cohorts of donors as well as clustering by age and/or grading of the disease, 
will presumably support sharper conclusions about the consistency of determined inflammatory 
and catabolic profiles in the different targeted populations.  
Regarding the OA-phenotypes of the different cells/tissues here used, the transcriptomic/secretory 
profiles of OA-Syn and OA-OC, were confirmed consistent with previous reports (193, 252). 
However, measured levels of cytokines such as IL1b, TNFa, IL8 and IL6 in OA-AC, were 
considerably lower than what described before on a different setup. In that same work, authors 
confirmed the significant effect that the culture of cells exerts on their secretory profile (174). 
Therefore, taking into account that the OA-AC here utilized were expanded and chondrogenically 
differentiated, it is likely to deduce that such processing further reduced their pro-inflammatory 
profile, and that results might then differ from in vivo/in human conditions. 
Overall, although the described results in this section indicate an anti-inflammatory and anti-
catabolic potential of N-TEC secreted factors, the implications of such effects in an in human 
situation cannot be established by means of these in vitro approaches. Complementary 
investigations are required to better understand this potential.  
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Better setups would consider, for example, more physiological OA-environments such as one 
allowing the cross talk between joint tissues and cell types, using animal models or experimenting 
with more biomimetic models in vitro, such as bioreactors. However, all these alternatives will 
correspondingly add another level of complexity (261). 
 
 Aim	 III:	 Compatibility	 of	 N-TEC	 within	 in	 vivo	 osteoarthritic	
environments.	 Survival,	 cartilaginous	 matrix	 maintenance	 and	
integration	with	surrounding	tissues.	
4.3.1 Introduction	
A typical OA joint environment is characterized by metabolic cues such as the production of 
inflammatory and catabolic factors by resident cells in cartilage (248, 262), synovial membrane 
(263, 264) and subchondral bone (218, 265); in addition to the mechanical stimuli playing a role in 
the development and progression of the disease. In these OA-conditions no cell-based treatment 
have been yet considered physiologically suitable (105, 221, 266), and for a successful therapy, 
both the survival of the graft - when exposed to the mentioned degrading conditions - as well as its 
integration with the surrounding cartilage and bone have to be demonstrated. This, as a critical 
condition to ensure stability of the joint, enable post-operative normal load distribution, and prevent 
future tissue degeneration (267).  
Evaluating survival and engraftment of any implantable structure, such as the nasal chondrocyte-
based engineered tissues (N-TEC) studied in this dissertation, is not feasible by means of in vitro 
models (as the described for aims I and II). These culture systems have the constraint of do not 
recapitulate thoroughly the features of an osteoarthritic joint (225), since they commonly involve 
only one of the afore mentioned components or an oversimplified version of them when combined. 
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Such modified representations may disregard, for example, the three-dimensional configuration or 
the tissue and/or the role of mechanical stimulation, neglecting the possible study of OA as 
multifactorial disease (224).  
With the aim of investigating the capacity of N-TEC to survive, integrate and maintain the 
cartilaginous matrix in a more physiological OA-environment, three different in vivo models were 
assessed in this thesis; two ectopic mouse models based on human osteoarthritic (i) engineered or 
(ii) explanted osteochondral tissues, and an (iii) orthotopic sheep model that was ‘chronified’ to 
mimic a degenerative scenario. This chapter summarizes the findings derived from assessing the 
performance of N-TEC in such OA-joint compartments simulated in vivo. 
4.3.2 Results	
4.3.2.1 Ectopic	model	of	engineered	OA-osteochondral	tissues	
4.3.2.1.1 N-TEC	 integrate	 and	 mature	 in	 vivo	 when	 combined	 with	 engineered	 bone	
compartments	generated	with	osteoarthritic	osteoblasts		
The first in vivo approach assessed the maturation and integration of N-TEC within an OA-
engineered osteochondral environment. N-TEC and bone-like tissues were separately engineered 
with GFP-labelled NC and OA osteoblasts (OA-OB), by pre-culture of the respective cells in 
chondrogenic or osteogenic medium during 3 to 5 days (Fig. 13A). Tissues were then combined to 
generate osteochondral constructs and ectopically implanted in mice for 8 weeks or maintained in 
vitro. After that time, N-TECs - both in vitro and in vivo - integrated with the underlying bone 
compartment (b) and produced cartilaginous matrix, as visualised by GAG staining with Safranin-
O (Fig. 13B). Only in vivo constructs evidenced the novo deposition of bone matrix in the 
subchondral compartment, with typical features of embedded osteocytes and lining osteoblasts 
(arrow and arrowhead on Fig. 13B magnification).  
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Higher intensity of the staining in the in vivo setup, indicated further maturation of the tissues as 
compared to the in vitro condition (Fig. 13E). Implanted constructs also showed positivity for type 
II collagen localized on the expected cartilaginous layer, confirming the cartilaginous composition 
of the deposited ECM (Fig 13C). In the same condition, type I collagen was only identified in the 
non-cartilaginous subchondral regions and in the superficial zone of the cartilage compartment, 
where remnants of the matrix material (composed of type I/III collagen) are expected (Fig. 13D). 
ECM of in vitro maintained constructs was not homogenously deposited and negative for the 
chondrogenic ECM marker collagen type II (Fig. 13F, G). 
The results obtained with this model indicate that N-TEC further mature in this in vivo environment 
when not fully differentiated prior implantation, maintain the deposited cartilaginous ECM, and 
integrate to OA-osteoblast-based (or containing) bone compartments. 
4.3.2.1.2 N-TEC	remains	avascular	and	contribute	to	the	formation	of	integrative	tissues	when	
combined	 with	 engineered	 bone	 compartments	 generated	 with	 osteoarthritic	
osteoblasts	in	vivo	
After verifying the integration and maturation of N-TEC within the engineered OA-osteochondral 
model, its capacity to remain avascular (as one of the features of healthy cartilage) and the role of 
the implanted cells in the integrative process were further investigated. To identify blood vessels, 
laminin staining was performed, and such structures found only in the bone compartment while not 
in the N-TEC zone (Fig. 14A). This demonstrating the capacity of N-TEC to mature into avascular 
cartilaginous tissues, even in close proximity with OA-osteochondral engineered tissues in vivo. 
To track cell fate 8 weeks after implantation, their human origin was identified by Alu in situ 
hybridisation throughout the entire construct (Fig. 14B). GFP-labelled cells were localized in the 
cartilaginous region and in the intermediate region between cartilage and bone (Fig. 14C), which 
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indicates that implanted NC participate in the formation of integrative tissue between the N-TEC 
and the bone compartment. 
 
Figure 13. Engineered OA-osteochondral constructs and their matrix deposition in vitro and in vivo. (A) Schematic 
representation of in vitro construct generation, by a combination of N-TEC (containing GFP+-NC) with a bone compartment 
(containing OA-OB) for posterior implantation in mice or in vitro culture. Safranin-O staining of (B) constructs after 8 weeks of 
implantation or (E) in vitro maintenance. Magnification of B shows the presence of an osteocyst (arrow) and a lining osteoblast 
(arrowhead) of an osteoid in the bone compartment. Collagen type II (C,F) or type I (D,G) immunostaining for constructs after 8 
weeks of implantation, or in vitro maintenance respectively. N-TEC= Nasal chondrocyte-based tissue engineered cartilage, b= bone 
compartment. Scale bar: 500 µm; 100 µm (magnifications on B,E).  
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4.3.2.2 Ectopic	model	of	OA-osteochondral	explants	
4.3.2.2.1 N-TEC	integrate	and	maintain	cartilaginous	matrix	in	vivo,	when	combined	with	OA-
osteochondral	explants		
Following the in vivo assessment into a simplified OA-osteochondral model (involving a single 
cell type, i.e., OA-OB), N-TEC performance was evaluated within osteoarthritic-osteochondral 
tissue explants (OA-OC), containing native OA cartilage and bone, as well as the corresponding 
cell types. Cartilaginous tissues were engineered with GFP-labelled NC, similarly to clinical 
manufacturing of human N-TEC (157). Following its generation, they were placed into cartilage 
defects, created in osteochondral tissues explanted from end-stage OA joints. Resulting constructs 
were either maintained in vitro, or subcutaneously implanted in mice for 8 weeks (Fig. 15A). Both 
in vitro (Fig. 15B) and in vivo (Fig. 15C) constructs deposited cartilaginous matrix, as observed by 
GAG detection with Saf-O staining.  
 
Figure 14. Characterization of implanted engineered OA-osteochondral constructs.  (A) Identification of vessels 
(pointed with arrows) in the osteogenic compartment by laminin immunofluorescence. (B) in situ hybridization for 
ALU sequence labelling human cells. (C) Immunohistochemical detection of GFP-positive NC. Pictures in bottom 
row show the magnification of indicated areas. N-TEC= Nasal chondrocyte-based tissue engineered cartilage, b= bone 
compartment. Scale bar: 500 µm (upper pictures); 100 µm (bottom pictures).  
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However, whereas in vitro N-TEC grafts remained disconnected from the surrounding 
osteochondral tissues, they integrated in vivo with the adjacent native cartilage and subchondral 
bone after 8 weeks of ectopic implantation (Fig. 15 D,E). Arbitrary scoring of integration (from 
absent=0 to complete=3) evidenced that, while in vitro maintained tissues displayed only poor 
integration with the surrounding cartilage, implanted constructs integrated to both cartilage and 
underlying bone, with a higher scored achieved between N-TEC and cartilage (Table 9). Inferior, 
but evident, integration between the graft and bone could be attributed to technical artefacts, such 
as the rudimentary preparation of the defects, leading to non-smooth interfaces (Fig. 1F). Further 
characterization of implanted OA-OC tissues evidenced the presence of MMP13 positive regions, 
indicating ongoing OA-related catabolic processes (Fig. 15G). In the graft area, cartilaginous 
composition of the deposited ECM was demonstrated by type II collagen positivity, while type I 
collagen was additionally detected as one of the main components of the scaffold (Fig. 15H).  
Table 9. Integration score for N-TEC within OA-osteochondral explants in vivo. Scoring of the integration 
between the graft (N-TEC) with the surrounding cartilage and underneath bone for in vitro maintained or in vivo 
implanted constructs. Score represents and arbitrary scale for no integration=0, poor integration=1, partial 
integration=2 and complete integration=3. Values presented as mean ±SD of n=5 in vitro constructs and n=6 in 
vivo samples.  
 N-TEC - cartilage N-TEC - bone 
in vitro 0.8 ± 0.4 0.0 ± 0.0 
in vivo 2.7 ± 0.6 1.8 ± 1.0 
 
To investigate the role of implanted cells in the formation of the integrative tissue, presence of 
human cells in the interfaces between N-TEC and both native cartilage and subchondral bone, was 
confirmed by Alu in situ hybridization (Fig. 16 A,B). Detection of GFP+ cells by 
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immunofluorescence evidenced the localization of implanted NC in the interstitial zone (Fig. 16C). 
All these data confirming, in a more physiological model than the previous engineered OA-
osteochondral tissue model, the capacity of N-TEC to integrate and maintain a cartilaginous matrix, 
as well as the ability of NC to survive and contribute to the integration process when placed into 
OA-environments in vivo. 
4.3.2.3 Orthotopic	Sheep	model	of	induced	OA	
4.3.2.3.1 Non	treated	articular	lesions,	induced	in	sheep	joints,	chronify	and	show	OA	signs		
After assessing the compatibility of NC within ectopic in vivo environments, integration of N-TEC 
and survival of the implanted cells were investigated in a load-bearing OA joint environment, 
recreated in an orthotopic sheep model. OA was induced in sheep joints (condyles) by generating 
full depth cartilage defects and leaving them untreated for 8 weeks (Fig. 17A). After OA induction, 
cartilage tissue in regions where the defects were created, presented macroscopic osteoarthritic 
marks, such as uneven and fibrous-like surface (Fig. 17B). Histological assessment confirmed lack 
of cartilage-specific proteoglycans in the tissue biopsies, received from the debrided areas (Fig. 
18C). Successful induction of OA was additionally demonstrated by the amount of synovial fluid 
which could be collected in higher amounts for the defected joint, as compared to the healthy one 
(0.52 ± 0.45mL vs 0.17 ± 0.21mL, respectively). In the collected samples, a trend of increase in 
levels of the pro-inflammatory/catabolic factors IL1β, TNFα, MMP1 and IL8 was observed (Fig. 
17D). No changes in the levels of additionally measured factors were detected, when comparing 
healthy and OA joints (Table 10).  
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Figure 15. Ectopic implantation of N-TEC grafts combined with osteochondral explants. (A) Schematic 
representation of human osteochondral construct formation, by combination of N-TEC (generated with GFP-labelled 
NC) within a cartilage defect in an osteoarthritic osteochondral explant (OA-OC). Formed constructs were maintained 
in vitro or subcutaneously implanted for 8 weeks in vivo. (B) Safranin-O staining of the construct after 8 weeks at 
control conditions in vitro or (C) in vivo. Magnification of indicated areas for Safranin-O staining of (D) N-TEC-
cartilage or (E) N-TEC-bone. (F) Safranin-O staining for a region with poor integration between N-TEC and the 
underlying bone compartment. (G) MMP13 immunofluorescence of implanted osteochondral tissues. (H) 
Immunofluorescent co-localisation of type II (red) and type I (green) collagen. N-TEC= Nasal chondrocyte-based 
tissue engineered cartilage, c= native cartilage, b= subchondral bone. Scale bar: 1mm (B,C), 100µm (D-H).  
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These observations indicate that the induction of OA-like defects, can be achieved after creation of 
defects on sheep joints, if left untreated. Such OA features, evidenced by macroscopic, histological 
and secretory changes, could provide and osteoarthritic environment in which to assess the 
performance of potential therapeutic products such as N-TEC. 
 
 
Figure 16. Presence of implanted nasal chondrocytes in the interstitial tissue. Human origin of cells confirmed by 
dark nuclear staining in (A) N-TEC and native cartilage, or (B) N-TEC and bone interfaces. (C) Detection of implanted 
cells by GFP immunofluorescence. Scale bar: 100µm. 
4.3.2.3.2 Engineered	cartilaginous	tissues-	based	on	sheep	nasal	chondrocytes	(sN-TEC)	can	be	
generated	and	their	properties	preserved	upon	implantation	in	OA-induced	defects		
Parallel to defect creation, sheep NC (sNC) were isolated from the same animal, GFP-labelled 
(transduction efficiency of 96.0-99.9%), expanded and used for the engineering of cartilage grafts 
(sN-TEC), similarly to clinical manufacturing of human N-TEC (157). After generation, grafts 
were implanted in the OA-induced defect sites and their performance assessed after 4 and 12 
months (Fig. 17A). Generated sN-TEC tissues, whose cartilaginous composition was confirmed by 
positive staining for GAG (Fig. 18A) and type II collagen (Fig. 18B), were implanted into the 
created OA-like defect. At the time of explantation, grafts were well-integrated into the recipient 
site and no further degeneration or signs of inflammation were macroscopically seen in the N-TEC 
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treated joints (Fig. 18 C,E). In coherence with the typical variability of large animal models, the 
repair tissue displayed various quality patterns (best and worst specimens shown in Fig. 18E).  
 
 
Figure 17. Experimental design and induction of OA-cartilage defects in sheep. (A) Experimental design of the 
large animal study. Sheep nasal chondrocytes (sNC) were GFP-labelled and seeded on ChondroGide® scaffolds to 
manufacture cartilaginous grafts (sN-TEC) that were further implanted into OA-induced cartilage defects for up to 12 
months. (B) Appearance of the osteoarthritic joint after OA induction. Circles indicate the area of debridement prior 
to graft transplantation. (C) Safranin-O staining of the debrided OA cartilage. (D) Protein levels of factors present in 
the synovial fluid of healthy and OA sheep (n=6 animals at each time point). Measured concentrations (pg/mL) were 
normalized to the volume of synovial fluid, per sample. Scale bar: 100µm. 
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Table 10. Inflammatory and catabolic factors on sheep synovial fluid. Concentrations for factors quantified in the 
synovial fluid of sheep (n=6) prior OA induction (=healthy), 8 weeks later at the time of N-TEC implantation (=OA) 
and 4-12 months after treatment (=treated). Values (in pg) represented as mean ±SD. Concentrations (pg/mL) were 
measured and normalized to the volume per sample. * indicates a significant difference of the treated group to the OA 
group defined by Mann-Whitney U test. Unilateral p<0.05 considered significant.  
  healthy OA treated 
IL1β 24.1 ± 53.9 317.5 ± 355.5 169.3 ± 338.6 
IL4 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
IL6 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
IL7 14.9 ± 29.7 1.1 ± 2.7 0.0 ± 0.0 
IL8/CXCL8 98.5 ± 104.7 488.0 ± 922.5 38.8 ± 44.9* 
IL10 7.9 ± 6.0 13.9 ± 13.3 6.0 ± 3.4 
IL13 0.0 ± 0.0 35.8 ± 55.6 16.6 ± 33.3 
TNFα 58.3 ± 27.9 206.9 ± 218.3 44.3 ± 49.2* 
MMP1  15229.6 ± 23556.8 93770.5 ± 196595.8 13137.7 ± 24476.7 
MMP3 364.0 ± 813.8 5813.2 ± 9542.2 537.7 ± 860.4 
MMP13 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
ADAMTS5 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
 
Volume of the synovial fluid obtained following the treatment was significantly decreased 
(0.17±0.16mL vs 0.52±0.45mL (p=0.047)), reaching the range of healthy joints (0,17 ±0.21mL). 
In one of the animals assessed at 12 months, no synovial fluid could be harvested at all. Some 
inflammatory cytokines in the collected synovial fluid samples decreased to ranges detected in 
healthy sheep (i.e., MMP1, MMP3, IL1β, IL10/CXCL10, IL13) (Table 10), or were significantly 
decreased as compared to the stage after OA induction and before treatment (i.e., IL8/CXCL8 and 
TNFα) (12.57-fold and 4.67-fold change respectively) (Fig. 18D).  
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Figure 18. Orthotopic implantation of sN-TEC into osteoarthritic cartilage defects in sheep. Quality of a 
representative sN-TEC prior implantation, (A) stained with Safranin-O and (B) assessed for type II collagen deposition. 
(C) Macroscopic appearance of cartilage repair at 12 months post implantation. (D) Protein levels of factors present in 
the synovial fluid of OA and N-TEC treated sheep (n=6 animals at each time point). Measured concentrations (pg/mL) 
were normalized to the volume of synovial fluid, per sample. (E) Histological staining (Saf-O) for best (upper) and 
worst (bottom picture) cartilage repair within the osteochondral tissues. Identification of implanted GFP positive sNC 
in explants after (I) 4 and (J) 12 months. Scale bar: 100µm. * = significantly different (p<0.05) between indicated 
groups, as assessed by Mann-Whitney-U tests.  
 
Implanted sNC could be tracked and identified by GFP immunofluorescence after 4 and 12 months 
(Fig. 18F, G). Cells were present both in the region of repair cartilage (r) (where grafts were 
presumably implanted, since borders were not always evident), and in the adjacent native cartilage 
(c) (Table 11). These results indicate sustained survival of implanted sNC in an OA joint and the 
capacity of sN-TEC to maintain cartilaginous features, while integrating with the surrounding 
tissues.  
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Findings described in this chapter demonstrate that when N-TEC is implanted in both ectopic and 
orthotopic in vivo OA-models, nasal chondrocytes can survive and contribute to the integration 
with adjacent tissues, while preserving the cartilaginous matrix. Moreover, and consistent with the 
findings of section 4.2 (Aim II), on treated joints of the orthotopic model, levels of circulating 
inflammatory factors were dampened, presumably due to the presence of N-TEC - or its secreted 
factors –.  
The in vivo models hence used, confirm the capacity of N-TEC to withstand OA-inflammatory 
conditions (Aim I) and to modulate the secretory profile of OA-cells (Aim II). In addition, the results 
summarized in this chapter demonstrate the compatibility of N-TEC within in vivo setups, in terms 
of integration with surrounding OA-tissues and further maturation of the implanted engineered 
cartilage. All these data suggest that in the context of an osteoarthritic joint, N-TEC could add to 
structural stability and reduce circulating levels of inflammatory and catabolic factors, which could 
have a potential disease modifying effect in long term.  
Table 11. Quantification of GFP positive (GFP+) cells in sheep condyles following N-TEC implantation. Ratio 
of the number of GFP+ cells (implanted nasal chondrocytes (NC) over total cells (stained in DAPI) for the indicated 
regions within the joints. Cells were quantified for two independent histological sections of each treated joint (n=8 
constructs at 4 months and n=16 constructs at 12 months). 
  4 months 12 months 
% GFP+ cells / total cells in cartilaginous layer 31.6 ± 17.5 23.9 ± 10.6 
% GFP+ cells in graft / total cells in graft 17.4 ± 15.3 10.6 ± 5.8 
% GFP+ cells in native cartilage / total cells in native cartilage 14.2 ± 10.9 13.3 ± 9.9 
% GFP+ cells in graft / total GFP+ cells in cartilaginous layer 49.6 ± 25.9 48.2 ± 22.5 
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4.3.3 Discussion	
Since no reliable pre-clinical models exist to predict the efficacy of cartilage repair in clinical OA 
settings, in this thesis different models were employed to address specific questions that could not 
be answered with the previously described in vitro models (sections 4.1, 4.2), and that must be 
investigated when  clinical application of a potential therapeutic agent is envisioned.  
In all in vivo models, it was demonstrated the capacity of nasal chondrocyte-based tissues to 
integrate with adjacent tissues and preserve the cartilaginous ECM, as required features for any 
structure to be implanted in an OA-environment. More specifically, the ectopic mouse model of 
engineered OA-osteochondral tissues, demonstrated that N-TEC could remain phenotypically 
stable, avascular, and efficiently integrate with underlying subchondral. The also ectopic, mouse 
model of human OA-osteochondral explants, could evidence cell survival and participation of the 
implanted cells in the formation of integrative tissue between N-TEC and both the OA-cartilage 
and subchondral bone. In this case, although the expression of a typical marker of cartilage 
degeneration in OA, MMP13 (268, 269), was still maintained in the OA osteochondral samples 
upon implantation (Fig. 15G), additional OA features such as secretion of inflammatory factors 
might not be preserved in such ectopic environment and therefore must be further confirmed. 
Complementary analysis such as immunohistological detection of pro-inflammatory and catabolic 
molecules, as well as secretory analysis of explanted tissues, could contribute to a better 
clarification for the maintenance of the OA-like environment.  
In these ectopic environments, absence of mechanical load and presumable loss of the OA- 
inflammatory status are not fully representative of the pathological features of an OA in vivo 
environment. Therefore, a large animal model of induced OA was therefore included with the aim 
of demonstrating the survival of implanted cells in an orthotopic site (load bearing), and for an 
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extended time than the assessed in ectopic models. Described results corroborate that implanted 
NC were detectable for at least 1 year after implantation in both the graft and the native cartilage 
areas, suggesting their participation into cartilage regeneration. In addition, this model allowed the 
analysis of synovial effusions, in which levels of inflammatory cytokines were reduced following 
the treatment with N-TEC. These findings support the indications of anti-inflammatory effect 
exerted by N-TEC released factors, as demonstrated when applied to OA-cells/tissues in vitro (Aim 
II).  
The large animal model of OA used in this study, constituted the more physiological environment 
employed in the entire study. In fact, the successful creation of an OA-like defect in these animals, 
could be confirmed by the increased volumes of synovial effusions of treated joints, as typical 
reported in human OA (171, 251, 270, 271). Increased secreted levels of pro-inflammatory and 
catabolic factors (IL1β, TNFα, MMP1 and IL8) also evidenced this OA-environment, as reported 
and observed in other studies.   
The here used ovine/sheep, is among the more commonly used and recommended to investigate 
orthotopic cartilage repair (234), and it have been employed in different setups, concerning the 
evaluation of MSC-based approaches for cartilage repair (272). Still, it is crucial to highlight that 
findings derived from this and other large animal studies, are not predictive of the clinical outcomes 
in patients (233, 273, 274),  mostly due to not only differences in biomechanics and physiology 
between species, but also to species-specific dissimilarities in disease pathology and progression, 
normal joint homeostasis and repair capacity (224, 274). 
Controlled clinical investigations in patients must be conducted to ultimately understand the 
performance of the here used N-TEC, in terms of human safety and therapeutic efficacy for the 
targeted lesions. Previous investigations of the group have demonstrated already safety and 
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feasibility of N-TEC in the context of cartilaginous focal lesions (157). Therefore, studies 
addressing efficacy and a standardised manufacturing will need to be conducted in order to bring 
this potential TE therapy into clinical practice (275). 
In regards to the capacity of NC to acquire the molecular identity of an implantation site (section 
3.3), it is important to consider that some alterations in the expression of factors such as the HOX 
genes are also reported in OA (276), and in particular in OA-AC that would key components of the 
implantation environment within an OA lesion (277). Assessing whether this altered pattern can be 
also acquired by NC, will be informative concerning a possible genetic limitation for the long-term 
performance of N-TEC under OA conditions, compromisingthe beneficial outcomes widely 
described in this whole thesis.  
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 Conclusions		
 
 
Aim I. Determining the capacity of N-TEC to form and maintain cartilaginous properties, when 
exposed in vitro to factors secreted by OA cells/tissues and pro-inflammatory cytokines. 
- Nasal chondrocyte-based engineered cartilaginous tissues (N-TEC) can maintain their tissue 
properties (determined by the content of cartilage ECM molecules, GAG and type II collagen) 
under inflammatory conditions simulating the onset of osteoarthritis (OA). When compared to 
A-TEC, this OA-withstanding capacity is superior for N-TEC in terms of ECM composition.  
- Effective triggering of a higher inflammatory profile – as in OA -, can be obtained in both 
nasal and articular derived tissues, by exposure to a chemically defined ‘low inflammation’ 
cocktail, as well as to medium conditioned by osteoarthritic synovial cells; as evidenced by 
the significant increased secretion of OA-associated markers IL6, IL8, TNFα and RANTES. 
Aim II. Evaluating the potency of N-TEC released factors to damper the production of 
inflammatory and catabolic molecules in OA cells/tissues in vitro. 
- Factors released by N-TEC can damper the inflammatory and catabolic profile of OA 
cells/tissue in a target specific manner: 
(i) In osteoarthritic articular chondrocytes (OA-AC) by significantly reducing gene expression 
levels of IL8, MMP13 and ADAMTS5, as well as MMP13 content. 
(ii) In osteoarthritic synovial cells (OA-Syn) by reducing gene expression levels of IL8, 
MMP13 and ADAMTS5 (similarly to the effect in OA-AC), and by down regulating the 
secreted concentrations of OA-associated markers (IL6, IL8, TNFα and RANTES).  
(iii) In osteoarthritic osteochondral explants (OA-OC) by down regulating the secreted levels of 
OA-associated markers (TNFα, MMP3 and ADAMTS4). 
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- The N-TEC secretome exert superior anti-inflammatory/catabolic properties than A-TEC, when 
applied to OA-AC and OA-Syn.  In opposition, A-TEC released factors can exacerbate the OA 
environment, by increasing the secretion of IL6 and IL8 in OA-AC (while N-TEC does not) and 
not down regulating the concentrations of IL6 and IL8 in OA-Syn (whereas N-TEC does).   
Aim III. Assessing the suitability of N-TEC for OA-environments simulated in vivo, in terms of cell 
survival, cartilaginous matrix maintenance and integration with surrounding tissues.   
- N-TEC can survive and integrate to surrounding tissues in different in vivo OA simulated 
models. Additionally, nasal chondrocyte-based tissues are able to: 
(i) Further mature and remain avascular (as evidenced in the ectopic model of engineered 
osteochondral tissues) 
(ii) Participate in the formation of integrative tissue within the graft (N-TEC) and both OA-
cartilage and underlying bone (as demonstrated in the ectopic osteochondral explant and 
sheep model) 
(iii) Maintain the previously described features for up to 12 months in a loaded orthotopic model 
of induced OA (in sheep), while reducing the circulating levels of the pro-inflammatory 
cytokines IL8 and TNFα, consistently to the observations in the in vitro models.  
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 Future	perspectives	
The findings derived from my PhD thesis indicate that nasal chondrocyte-based engineered tissues 
(N-TEC) can be indeed envisioned as suitable treatment of osteoarthritic defects, regarding their 
well confirmed capacity to preserve the cartilaginous properties under diverse OA simulated 
conditions, confirmed so far in vivo for up to 12 months (in the sheep model). In fact, due to the 
positive results here described, and considering the previously demonstrated safety and feasibility 
of  N-TEC to treat post-traumatic cartilage defects (published by our group in The Lancet, 2016); 
two young patients diagnosed with medial compartmental OA, have been treated with autologous 
N-TEC, having positive outcomes for up to 22 months (which is the latest available follow up). 
These two clinical cases were intervened following authorization by Swissmedic, and otherwise 
considered for prosthetic joint replacement (not indicated for their age range). The main outcomes 
included no adverse reactions and formation of repair tissue at the level of the surrounding 
cartilage, as well as reduction in self-reported scores of pain and disability. These results, along 
with the in vitro/in vivo data comprised in this thesis, have been submitted to the journal of Science 
Translational Medicine, and is currently under revision.  
Regarding this clinical application of N-TEC in OA, it is important to bear in mind that there are 
not animal models accepted by competent authorities as predictive of the clinical efficacy for this 
disease. Therefore, further investigations should focus on the efficacy assessment in the frame of a 
phase II study, in terms of the evaluation of the long-term performance of the graft, and in the 
clarification of the neat effect of N-TEC in the mentioned outcomes, since additional mechanical 
correction was performed along in both patients. However, although additional surgical 
manipulation can influence the recovery of structural aspects in the joint, it is not expected to have 
any disease modifying capacity. This consideration is relevant in view of the anti-inflammatory 
and anti-catabolic features displayed by N-TEC, both in vitro and in vivo. Such potential could 
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provide, for the first time, a possible strategy for disease-modification of OA, thus avoiding or 
delaying the irreversible intervention of joint replacement. Further investigations including the 
assessment of presence and composition of synovial fluid, along with the evaluation of the fibrotic 
or hyaline character of the formed repair tissue, could be the envisioned strategy to elucidate the 
long- erm scope of these results.  
In view of further trials, the potential efficacy of N-TEC for the repair of OA-defects must be also 
investigated in comparison to commonly used treatments such as the injections of hyaluronic acid. 
This would be helpful in order to establish whether the implantation of N-TEC can improve the 
clinical outcome over those standard treatments. In addition, the possibility of combining N-TEC 
with other treatments/drugs could be contemplated as a strategy to counteract the appearance of 
adverse events such as hypertrophy.  
Considering the variety of disease etiologies, either from single or multiple factors, extremely 
heterogeneous patient groups are found, and it is rather unlikely that one treatment can be effective 
for all patients. Therefore, it is also important to identify biomarkers that can be used for selection 
of ‘responders’ to a certain therapy, such as N-TEC implantation. Prediction of outcomes before 
treatment would avoid unnecessary risks for the patient, and lead to reduction of health care costs, 
as treatment would only be attempted in potentially responsive patients. In addition, identification 
of biomarkers and understanding of the associated pathways will aid in the development of 
improved treatment options and in the understanding of the disease mechanisms.  
Foreseeing a better understanding of the biology of nasal chondrocytes (NC) and their distinct 
nature from articular (AC) ones, a comparative transcriptomic profiling been performed by our 
group, identifying 1,726 genes differentially expressed between both cell types. In the context of 
the inflammatory focus of my research, 17 of these differentially expressed genes have been 
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detected as related to inflammation, suggesting a differential role in the OA environment. However, 
the establishment of differential features related to other pathways important for cartilage formation 
such as Wnt (wingless/integrated-1) and BMP (bone morphogenic proteins), among others, will 
require further analysis and investigation.  
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 Materials	and	Methods	
 Materials	
7.2.1 Table	12.	Equipment	
Item Reference Manufacturer 
Elisa reader 
Synergy H1 Hybrid Multi-Mode 
Reader 
BioTek 
Tissue processing center TPC 15 Duo Medite 
Tissue embedding station TES Valida MEDITE 
Sliding Microtome HM 430 Thermo Fisher Scientific 
Inverted microscope Eclipse Ti2 Nikon 
Luminex Reader Bio-Plex 200 Bio-rad 
Real-Time PCR 
cycler/detector 
Applied Biosystems 750 Thermo Fisher Scientific 
Flow cytometer Accuri C6 BD biosciences  
 
 
7.2.2 Table	13.	Cell	supports/Scaffolds	
Material Reference Manufacturer 
Non-adherent U bottom 96-well plates 268200 Thermo Fisher Scientific 
Collagen-based sponge ChondroGide,  Geistlich Pharma AG 
Ceramic scaffold Engipore  Finceramica 
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7.2.3 Media	composition	
 
Table	14.	Basic	medium	
 Reference Manufacturer 
Dulbecco’s modified medium (DMEM) 10938-025 Invitrogen 
10 mM HEPES 15630-056 Invitrogen 
1 mM sodium pyruvate 11360-039 Invitrogen 
100 U/ml penicillin-streptomycin-glutamine 
(PSG) 
10378-016 Invitrogen 
	
Table	15.	Chondrogenic	medium	
Based on basic medium and with the following supplements 
   For differentiation in 
 Reference Manufacturer 
micro/macro-
masses 
Collagen 
based-scaffold 
20 % Human serum albumin 
(HSA)  
43075 CSL Behring x  
10ng/mL TGF-β3  -  Novartis x  
50mM Ascorbic acid (AA) -  A-8690 Sigma x x 
Insulin-Transferrin-Selenite 
(ITS) 
51300-044 Gibco x  
Linoleic acid L9530-5 Sigma x  
10−7M Dexamethasone 
 
D-2915 Sigma x  
10µg/mL Insulin Actrapid HM 
Novo Nordisk 
Pharma AG 
 x 
5% FBS* 10270-106 Invitrogen  x 
* For manufacturing of the N-TEC implanted in patients, autologous serum used instead. 
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Table	16.	Osteogenic	medium	
 Reference Manufacturer 
Minimum Essential Medium α (αMEM) 22571-020 Invitrogen 
10% FBS 10270-106 Invitrogen 
0.1 mM Ascorbic acid (AA)  A-8690 Sigma 
10 mM Sodium beta glycerolphosphate 
pentahydrate G-9891 Sigma 
10 nM Dexamethasone D-2915 Sigma 
 
7.2.4 Table	17.	Antibodies	
  Dilution Reference Manufacturer 
Primary 
Type II collagen 1:5000 34712 Abcam 
Type I collagen 1:1000 138492 Abcam 
GFP 1:1000 1020 Aves Lab 
MMP13 1:500 39012 Abcam 
Laminin 1:250 11575 Abcam 
Secondary 
Alexa Fluor 568 1:200 A11041 Thermofisher Scientific 
Alexa Fluor 488 1:200 A11008 Thermofisher Scientific 
Alexa Fluor 647 1:200 A21241 Thermofisher Scientific 
Biotinilated AB for 
GFP IHC 1:300 BA-1400 Vector Laboratories 
 
7.2.5 Table	18.	Primers	and	probes	
 Reference TaqManTM assay Manufacturer 
COL2 Hs00264051 
Thermofisher Scientific 
COL1 Hs00164004 
ACAN Hs00153936 
MMP13 Hs00233992 
MMP3 Hs00968305 
ADAMTS5 Hs00199841 
IL8 Hs00174103 
IL6 Hs00985639 
GAPDH Hs02758991 
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7.2.6 Table	19.	Detection	assays	
 Reagent Reference Manufacturer 
Biochemical 
methods 
Dimethylmethyleneblue 
(DMMB) 
341088 Sigma 
Chondroitin sulfate C9819 Sigma 
Bacteriophage λ DNA 
C7026 Invitrogen 
CyQuant 
Staining 
Safranin-O 84120 Sigma 
Fast-Green F-72552 Sigma 
Hemaetoxylin 3873 J.T. Baker 
Goat serum 16210-064 Invitrogen 
Vectastain kit (phospathase-
substrate) 
AK-5000 Linaris 
Hyaluronidase H3884 Sigma 
Dapi DI306 Thermofisher Scientific 
Pronase 10 165 921001 Roche 
Gene 
expression 
analysis 
Quick-RNA™ Miniprep Plus 
Kit 
R1054 Zymo Research 
SuperScript™ III reverse 
transcriptase 
18080044 Invitrogen 
Protein assays 
Luminex kit 
Magnetic customized 
Assay 
R&D Systems 
Human MMP13 ELISA 
Sensolyte® Plus 520 
Assay  
Anaspec 
Human ADAMTS4 and 5 
ELISA 
Duo Set DY219805, 
DY430705  
R&D Systems 
Sheep ELISA  
IL1β, IL6, IL8/CXCL8, IL10, 
TNFα, IL4, IL7, IL13, MMP13 
(MBS734810),(MBS76050
4),(MBS025204),(MBS704
435),(MBS763586),(MBS7
36299),(MBS925047),(MB
S043750), (MBS2511038) 
My BioSource 
Bovine ELISA 
MMP1, MMP3, ADAMTS5  
(MBS031074),(MBS93107
94), (MBS933409) 
My BioSource 
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7.2.7 Table	20.	Additional	reagents	
Reagent Reference Manufacturer 
Type II collagenase 4176 Sorthington 
Trypsin  25300-096 Invitrogen 
IL1β I9401 Sigma 
TNFα H8916 Sigma 
IL6 206-IL R&D Systems 
Protein kinase P2308 Sigma Aldrich 
PBS 20012-068 Invitrogen 
EDTA S4881 Sigma 
Fibrin glue Tisseel Baxter 
 
 Methods	
7.3.1 Cell	biology	methods	
7.3.1.1 Regulatory	compliance	for	human	and	animal	studies	
All human samples were collected with informed consent given by the involved individuals and/or 
relatives. All animals were treated in agreement with the Swiss legislation with approval by the 
Veterinary Office of Canton Basel-Stadt (permission # 1797, for experiments with mice) and the 
responsible veterinary office of Zürich (Kantonales Veterinäramt Zürich, for sheep studies). 
Studies on human patients were approved by EKNZ (the cantonal ethical authority of Basel 
Ethikkomission Nordwest- und Zentralschweiz) and by Swissmedic (Swiss Regulatory agency for 
therapeutic products).  
7.3.1.2 Cell	and	tissue	isolation		
7.3.1.2.1 Chondrocytes	
Nasal chondrocytes (NC) were isolated from the nasal septums (n=14) of human donors obtained 
as residual tissue from surgical interventions or post-mortem.  Healthy articular chondrocytes (AC) 
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(n= 9), were taken from regions of healthy-looking cartilage (i.e., no fibrous, soft or vessel invaded 
areas) from joints of patients undergoing engineered cartilage implantation, or from articular 
tissues harvested post-mortem. For osteoarthritic articular chondrocytes (OA-AC), cells were 
isolated from evidently degenerated joints from patients undergoing knee replacement (n=9).   
Cartilage from all sources was mechanically dissected and enzymatically digested with collagenase 
(1.5mg/mL, 22 hours). After, enzyme was washed away by centrifugation (1500rpm, 3min) and 
cells plated and expanded for up to 3 passages in expansion medium (basic medium containing 
1ng/mL TGF-β1 and 5ng/mL FGF-2), using culture flasks and at a seeding density of 5.000 to 
10.000 cells/cm2. All cultures were maintained at 37°C and 5% CO2 in this and further steps.  
7.3.1.2.2 Osteoarthritic	cells	and	tissues	
All OA tissue biopsies were collected from patients undergoing total knee replacement. OA-Syn 
(n=12) and OA-OB (n=1) were obtained by outgrowth culture of synovial membrane and 
subchondral bone biopsies, respectively, and cultured as previously described (252, 278).  OA-OC 
(n=3) were isolated from tibias, chopped into pieces and either kept in control medium (basic 
medium 2% FBS) (CTR) overnight - prior exposure to the corresponding treatments -, or 
maintained in osteogenic medium for production of conditioned medium.  
7.3.1.3 Chondrogenic	differentiation	
Expanded cells were detached by trypsinization (3min) to be further re-differentiated in macro and 
micro-masses (sections 4.1 and 4.2) or in scaffolds (section 4.3). For macromases (N-TEC/A-TEC 
and OA-OC aggregates), pellets were generated through centrifugation (1500rpm, 3min) of 
250.000 cells (256) in non-adherent 96 well plates, and cultured in chondrogenic medium for up to 
14 days. Micromases were treated as previously described (254). Briefly, about 100 cells were 
seeded on a microfluidic device with multiple cubic chambers (side of 150 μm) to obtain 
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microaggregates that were then allowed to condensate at static condition for one day, followed by 
7 days of differentiation within the device in serum-free chondrogenic medium (same that for 
macromases) under continuous perfusion (0.5 μl/h). 
Differentiation in scaffolds was performed by seeding the chondrocytes at a density of  4.2x106 
cells/cm3 in a collagen-based sponge (8mm diameter), to be further differentiated during two 
weeks, according to protocols for clinical grade manufacturing of human nasal chondrocytes-based 
grafts (157). In all cases, medium change was performed twice a week. 
7.3.1.4 Generation	of	conditioned	media		
7.3.1.4.1 From	osteoarthritic	cells/tissues	
From OA-OC: Pieces were harvested, and processed as previously described (193), by cutting them 
into pieces of about 9cm2, and individually culturing the fragments for 7d in 8mL of osteogenic 
medium. From OA-Syn: Isolated cells were seeded on a density of 1x105 cells/ml in CTR media 
during 3d. At the end of each culture period, supernatants were collected and used as a pool.  
7.3.1.4.2 From	Nasal/Articular	chondrocytes	
To apply into OA-OA aggregates, N-TEC and A-TEC were cultured (in scaffolds for application 
on OA-AC, and in macromases for application in OA-Syn) in CTR medium at a density of 
5x106cells/mL. In both cases, supernatants were collected after 72h to be used as conditioned 
medium (N-TEC_CM/A-TEC_CM). 
7.3.1.5 Cell/tissue	treatments	
7.3.1.5.1 Exposure	of	N-TEC/A-TEC	to	OA-simulating	conditions	
Re-differentiated nasal or articular chondrocytes in the form of TEC, were culture for up to 2 weeks 
in CTR mediu or different inflammatory conditions: (i) Low inflammation (CTR containing 
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50pg/mL IL1β, 50pg/mL TNFα,100pg/mL I6); (ii) High inflammation (CTR with 500pg/mL 
IL1β, 500pg/mL TNFα,1000pg/mL IL6); (iii) OA-Syn_CM  (50% CM/ 50% CTR and (iv) OA-
OC_CM (30% CM/ 70% CTR). During the exposure time, medium containing the corresponding 
factors was renewed twice a week and at the end of the culture, TECs were harvested and stored 
for analysis. 
7.3.1.5.2 Exposure	of	OA-cells	and	tissues	to	conditioned	media	
After chondrogenic differentiation, aggregates of OA-AC were culture in N-TEC/A-TEC_CM 
medium during 7d before analysis. OA-Syn (in monolayer) and OA-OC (in pieces of 0.25cm2 
aprox), were also cultured in the conditioned medium from N-TEC and A-TEC for up to 14 and 7d 
before further processing.   
7.3.1.6 Generation	of	N-TEC/OA-OC	constructs	
7.3.1.6.1 Engineered	model		
Expanded human NC were labelled with GFP via lentiviral transduction (280) and cultured in 
collagen-based sponges (6 mm diameter) for 4 days in basic medium (5% FBS) containing TGF-
β3, AA and insulin. In parallel, OA-OB 3-4.5x103/mm3 were seeded on cylindrical ceramic 
scaffolds (6 mm diameter, 4 mm high) and cultured in osteogenic medium. At day 4, N-TEC were 
combined with the bone-cylinders seeded with OA-OB, using fibrin glue. Constructs were 
incubated for 24 h in basic medium (supplemented with 2% FBS, AA, dexamethasone, 
glycerophosphate) prior subcutaneous implantation. Identically generated constructs were 
maintained in parallel in vitro for the same time. 
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7.3.1.6.2 Explant	model	
One day prior implantation, a defect of 6mm2 was created in the cartilage layer of the osteoarthritic 
osteochondral (OA-OC) tissues by a combination of punching and spooning out the unwanted 
tissue. Afterwards, the generated N-TEC were also punched to the same diameter than the defect 
and placed into for further implantation of the combined construct. Uncombined N-TEC and OA-
OC plugs were left as controls.  
7.3.1.6.3 Ectopic	Implantation	
Constructs of the respective models in nude mice (Nu/Nu, Charles-River, Sulzfeld, Germany) for 
8 weeks as previously described (281). Two to three constructs (combinations or controls) were 
implanted per animal. Additional OA-OC, N-TEC and OA-OC+N-TEC were kept in culture as in 
vitro controls.   
7.3.1.6.4 	Sheep	model	7.3.1.6.4.1 Defect	creation	
OA was induced as described before in caprine models (282), by generation of four full thickness 
cartilage defects of 4mm in diameter/animal (2 per condyles) in female white Swiss alpine sheep 
(n = 6 ) (71.0 ± 4.1 kg; 1.5 - 2.5 years). Defects were left untreated until implantation (for 8 weeks) 
under free movement and load bearing, with no mechanical support.  
7.3.1.6.4.2 Autologous	sheep	N-TEC	in	osteoarthritic	articular	cartilage	defects	
Sheep NC were isolated (n=6 animals), for generation of sheep N-TEC (sN-TEC) as previously 
described (143). Briefly, circular biopsies of 6mm in diameter were harvested and kept in transport 
medium (PBS, 500ng/mL fungizone, 200U/mL PSG) till processing. Once in clean conditions 
samples were fragmented, enzymatically digested and expanded for two passages. At this stage, 
cells were GFP-labelled as previously described (156) by plating 4x103cells/cm2 overnight in basic 
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medium (2% FBS) to then add a lentiviral suspension (MOI 10) in the presence of polybrene 
(2µg/mL) during 4 hrs, time after which cells were back to basic medium. Transduction efficiency 
was inspected either visually or by FACS 24hrs after viral exposure.  
Three weeks prior implantation sNC were thawed, let attached to plastic for 24hr and used for 
chondrogenic differentiation in scaffolds according to protocols for clinical N-TEC manufacturing 
(157). After that, autologous sN-TEC were implanted into the OA induced defects and left for up 
to 12 months.  
7.3.2 Analytical	methods	
7.3.2.1 Tissue	quality	characterization	
7.3.2.1.1 Fixation,	paraffin	embedding	and	cutting	
After culture phase, engineered cartilaginous tissues were stored in formalin overnight at 4°C, and 
afterwards washed with PBS, dehydrated and embedded in paraffin by means of an automatic 
immersion device and a tissue embedding station. Embedded tissues were then sectioned (4 to 6µm 
thickness) and stained for different molecules upon rehydration. For osteochondral tissues, a step 
of decalcification with EDTA was introduced (283) (up to 4 months according to the size) prior 
paraffin embedding. 
7.3.2.1.2 Safranin-O:		
Proteoglycans present on the sections were detected with Safranin-O as previously described (243), 
and counterstaining with fast-green and hematoxylin. Colored sections were permanently mounted 
for imaging.  
7.3.2.1.3 Immuno-detection		
Sections were enzymatically digested, with hyaluronidase (2mg/mL, 15 to 30min) and pronase 
(1mg/mL, 30 to 60min) at 37°C. Then, sections were washed, and goat serum used to block non-
 
 
101 
specific epitopes prior antibody exposure overnight. Afterwards, for immunohistochemistry (IHC), 
matching biotinylated-secondary antibodies were used (2hr at RT) and biotin positive regions 
detected with alkaline phospathase coloured-substrate-binding complexes. Finally, nuclei were 
stained with hematoxylin and slides mounted and imaged. For immunofluorescence (IF), sections 
were treated as for IHC staining until primary antibody exposure. After, a matching secondary 
antibody fluorochrome-conjugated was used for detection. Nuclei were stained with Dapi 
(300mM). For micropellets, IF analyses were performed as previously described (284). 
7.3.2.1.4 Alu	in	situ	hybridization	
Detection of Alu genomic sequences was performed as described before (143). Briefly, 
hybridization was performed over night at 42°C on paraffin sections using a digoxygenin labelled 
probe specific for human Alu genomic repeats, and identified with an alkaline phosphatase 
conjugated antibody.   
7.3.2.2 Biochemical	characterization		
Engineered tissues were digested in 500 µL of protein kinase (1mg/mL) at 56°C during 16hrs and 
the obtained suspension, processed immediately or stored at -20°C for the subsequent analysis.  
7.3.2.2.1 GAG	quantification:		
Glycosaminoglycans were measured in the digested engineered tissues as previously described 
(285), by homogenizing 20 µL of the sample in 1mL of dimethylmethylene blue (DMMB) to allow 
cluster formation. Then, samples were centrifuged to recover the GAG-DMMB complexes as 
pellets, to be further dissolved and spectrophotometrically quantified. GAG concentration on the 
assessed TECs were determined through interpolation of a typical Em/Concentration standard 
curve prepared with Chondroitin Sulphate.  
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7.3.2.2.2 DNA	quantification:		
DNA was quantified in digested tissues with CyQuant assay according to manufacturer 
instructions. DNA was then measured spectrophotometrically. Concentration on targeted samples 
were determined by interpolation of an Emission/Concentration standard curve prepared with 
bacteriophage λ DNA. 
7.3.2.3 Image	acquisition	and	processing	
Bright field and fluorescent images were acquired with an inverted microscope. No additional 
processing was done on bright field captures, while fluorescent images further processed with the 
Fiji image processing package in order to compose RGB pictures. 
7.3.2.3.1 Histological	evaluation	of	engineered-tissue	quality		
Quality of the obtained tissues was assessed visually on Safranin-O stained sections using the Bern 
Score (243). Each sample was graded from 0 to 3 arbitrary units, in terms of (A) uniformity and 
intensity of the staining, (B) distance between cells/amount of matrix produced and (C) cell 
morphology. Three independent observers judged all parameters, and the grades averaged for a 0 
to 9 global qualification; being 0 the lowest and 9 the highest cartilaginous quality.  
7.3.2.3.2 Quantification	of	Safranin-O	staining	
Indirect quantification of GAG content was performed by measuring of the optical density (OD) 
of Safranin-O by deconvolution of the RGB images and subtraction of the OD for fast green and 
hematoxylin, assuming stoichiometric staining (286). The intensity range was defined from min (= 
darkest pixel) to max (=the empty area of the image) and calculated for the whole image as an 
average from all pixels, normalized by the max intensity. Values where then correlated with 
visually scored samples for the (A) parameter in the BernScore (previous section) to set the 
measurments between 0 and 3, according to the stablished scale. Analysis were performed with 
Fiji.  
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7.3.2.3.3 GFP	quantification	for	detection	of	NC	in	sheep	samples	
Total cells (DAPI) and GFP-positive NC were quantified through bright spot counting in the 
corresponding channels (General Analysis tool, NIS-Elements software). Percentage of GFP-
positive cells out of all DAPI positive cells were calculated in the graft area (defined as the 
presumed graft area  - that may include up to 100 µm of adjacent cartilage since the definite borders 
were not always clearly definable -) or in the interzone (defined as the whole cartilaginous layer 
without the graft area). Both graft and interzone included approximately 50 µm of the underneath 
calcified cartilage/subchondral bone. Quantification was performed for 2 individual section of each 
construct. 
7.3.2.4 Gene	expression	analysis	
For cells and macromases, stored samples (-80°C) were thawed and sonicated (in the case of 
engineered tissues) prior total RNA isolation and purification with a miniprep Kit, according to 
manufacturer instructions.  In the microfluidic device, microaggregates were perfused with PBS 
for 10 minutes (100 µl/h), and subsequently with lysis buffer for 10 minutes (300 µl/h) to be 
recovered downstream in a collection tube before preparing the miniprep. 
For qRT-PCR, the extracted RNA was retrotranscribed to cDNA with SuperScript transcriptase 
following supplier protocol, and the product of the reactions used for quantitative PCR to determine 
expression levels of COL2, COL1, ACAN, MMP13, MMP3, ADAMTS5, IL8 and IL6 and GAPDH 
as housekeeping gene. Specific primers are reported in Table 18. Upon amplification, CT values 
were analyzed with the 2-ΔΔCT method (287).  
7.3.2.5 Protein	quantification	
For in vitro experiments, supernatants from the different conditions were collected at the specific 
time points and stored at -80°C until processing. Samples were then thawed and centrifuged at 
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16.000xg during 4 min to remove particulates and then used for the different assays. IL1β, IL6, 
IL7, IL8, IL12, IL17, Eotaxin, GCSF, IFN, IP10, MCP1, MIP1α, MIP1β, RANTES, TNFα, IL4, 
IL10, IL13, IL1Ra and MMP3 were quantified by Luminex; MMP13, ADAMTS4 and ADAMTS5 
by ELISA.  
For sheep synovial fluids, cytokine concentrations were determined with sheep specific kits for 
IL1β, IL6, IL8/CXCL8, IL10, TNFα, IL4, IL7, IL13, MMP13 and - due to a lack of sheep specific 
ELISAs -, with bovine assays for MMP1, MMP3 and ADAMTS5. 
7.3.2.6 Statistical	analyses	
All data are presented as mean values ±SD (standard deviation). For each donor and experimental 
group, technical duplicates or triplicates were performed. Multiple comparisons were assessed by 
Kruskal Wallis and pairs by Mann Whitney-U test, when this last comparison was used as post hoc 
correction of the P value with the Bonferroni method was done. P values < 0.05 were considered 
significant. Sample size and specific analysis are indicated on each figure. All comparisons were 
done with the SPSS statistical package. 
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Appendix	
 
	
List	of	Abbreviations	
 
A-TEC  tissue engineered cartilage derived from articular chondrocytes  
A-TEC_CM  medium conditioned by A-TEC_CM 
AA   ascorbic acid 
AC   articular chondrocytes 
ACAN  encoding gene for aggrecan 
ACI   autologous chondrocyte implantation 
ADAMTS a  disintegrin and metalloproteinases with thrombospondin motif 
ASC   adult stem cell/progenitors 
BMP   bone morphogenic proteins 
COL2/1  encoding gene for type II/I collagen 
COMP  cartilage oligomeric protein 
DMD   disease modifying drugs 
ECM   extracellular matrix 
EGF   epidermal growth factor 
ESC   embryonic stem cells 
FGF  fibroblastic growth factor 
GAG   glycosaminoglycans 
GFP   green fluorescent protein 
HA   hyaluronic acid 
HOX   subset of homeobox genes 
IGF   insulin growth factor 
iPSC   induced pluripotent stem cells 
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ITS   insulin-transferrin-selenium 
MACI  matrix-based autologous chondrocyte implantation 
MMP   matrix metalloproteinases 
MSC   mesenchymal stromal cells 
N-TEC  tissue engineered cartilage derived from articular chondrocytes 
N-TEC_CM  medium conditioned by N-TEC 
NC   nasal chondrocytes 
NSAIDs  nonsteroidal anti-inflammatory drugs 
OA  osteoarthritis 
OA-OC_CM  medium conditioned by osteoarthritic osteochondral tissues 
OA-Syn_CM  medium conditioned by osteoarthritic synovial cells 
OAT   osteochondral allograft transplantation 
OB   osteoblast  
OC   osteochondral tissus/explants 
OCT   osteochondral autograft transplantation 
PG   proteoglycans 
RANTES  Regulated upon Activation, Normal T cell Expressed, and Secreted cytokine 
Syn   synovial cells 
TE   tissue engineering 
TGF-b  transforming growth factor beta 
TNFsR  tumor necrosis factor soluble receptor 
TNFα  tumor necrosis factor alpha 
TSP   thrombospondin 
TSPSC  tissue specific progenitor stem cells 
VEGF  vascular endothelial growth factor 
Wnt   wingless/integrated-1 protein 
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